var title_f4_19_4400="Linear ulcers Crohns Endosc";
var content_f4_19_4400=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68093&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Linear ulcerations in Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 183px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Colonoscopy shows linear ulcers that can course for several centimeters along the longitudinal axis of the colon in Crohn's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_19_4400=[""].join("\n");
var outline_f4_19_4400=null;
var title_f4_19_4401="Radial growth arrest";
var content_f4_19_4401=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radial growth arrest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Anteroposterior x-ray of radial growth arrest and ulnar overgrowth after physeal fracture. Patient complained of ulnar-sided wrist pain and clicking. B) Clinical photograph of ulnar overgrowth and radial deviation deformity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Waters PM, Mih AD. Fractures of the distal radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_19_4401=[""].join("\n");
var outline_f4_19_4401=null;
var title_f4_19_4402="Sequestration CT II";
var content_f4_19_4402=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intralobar sequestration right lower lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan shows a right basilar multicystic mass with systemic arterial supply.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_19_4402=[""].join("\n");
var outline_f4_19_4402=null;
var title_f4_19_4403="High altitude illness (including mountain sickness)";
var content_f4_19_4403=[" <h1 id=\"patTopicTitle\">",
"  Patient information: High altitude illness (including mountain sickness) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?4/19/4403/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4403/contributors\" id=\"au2386\">",
"       Scott A Gallagher, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4403/contributors\" id=\"au2979\">",
"       Peter Hackett, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?4/19/4403/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4403/contributors\" id=\"se864\">",
"       Daniel F Danzl, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?4/19/4403/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4403/contributors\" id=\"de97\">",
"       Jonathan Grayzel, MD, FAAEM",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?4/19/4403?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Traveling to high altitudes can cause an altitude-related illness, such as acute mountain sickness (AMS), swelling of the brain (high altitude cerebral edema or HACE), or accumulation of fluid in the lungs (high altitude pulmonary edema or HAPE).",
"    </p>",
"    <p>",
"     It is possible to prevent these conditions by ascending slowly and allowing your body to adjust as you go. Serious complications of high altitude disease can usually be avoided by watching for early signs and symptoms of high altitude illness and responding quickly.",
"    </p>",
"    <p>",
"     This article will review the prevention and treatment of high altitude illness. More detailed information is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link\">",
"      \"Acute mountain sickness and high altitude cerebral edema\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     It is not possible to know in advance if you will become ill when traveling to a high altitude. In addition, being physically fit does not decrease your chances of developing a high altitude illness. However, certain groups are at increased risk, including people who:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Have a prior history of high altitude illness",
"      </li>",
"      <li>",
"       Exercise or drink alcohol before adjusting to the change in altitude",
"      </li>",
"      <li>",
"       Ascend rapidly (less than one day to sleeping altitude over 9000 feet, or 2700 meters)",
"      </li>",
"      <li>",
"       Have a medical problem that affects breathing",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PREPARING TO TRAVEL",
"     </span>",
"    </p>",
"    <p>",
"     If you will be sleeping above 8000 feet (2400 meters), you should make an appointment with your healthcare provider before your trip. During this visit, you should discuss your travel plans, availability of medical care at your destination, and the potential need for medicines to prevent",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     treat high altitude illness. (See",
"     <a class=\"local\" href=\"#H10\">",
"      'AMS treatment'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Traveling with medical conditions",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with certain medical conditions need to take special precautions when traveling at high altitudes:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If you have diabetes and you check your blood sugar, be aware that blood glucose meters can give inaccurate results at high altitudes. Consult the manufacturer of the meter for recommendations about high altitude readings.",
"      </li>",
"      <li>",
"       If you have angina or had a heart attack in the past, check with your doctor to be sure that it is safe to travel to high altitudes. If you develop chest pain, shortness of breath, or dizziness while traveling, seek medical help immediately.",
"      </li>",
"      <li>",
"       Asthma does not worsen at high altitudes.",
"      </li>",
"      <li>",
"       If you use oxygen because of lung disease, you will need a higher oxygen flow rate at high altitude. If you do not need oxygen for your lung disease at home, you might need oxygen at high altitude. Check with your doctor before you travel. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?32/22/33122?source=see_link\">",
"        \"Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       If you have sickle cell disease, you will probably need oxygen if you travel above 7000 feet (2100 meters). If you have sickle cell trait (some people do not know they do), altitude-related complications (eg, infarction of the spleen) can occur, even at altitudes below 9000 feet (2700 meters).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      ACUTE MOUNTAIN SICKNESS",
"     </span>",
"    </p>",
"    <p>",
"     Acute mountain sickness (AMS) is the most common of the altitude diseases; it occurs in approximately 40 to 50 percent of people who live at a low altitude and sleep at an altitude above 10,000 feet (3000 meters), and in approximately 25 percent of those sleeping above 8000 feet (2400 meters).",
"    </p>",
"    <p>",
"     Symptoms usually occur within 6 to 12 hours of arrival at altitudes above 8000 feet (2400 m). Symptoms can begin as soon as one hour or as long as 24 hours after arriving.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      AMS prevention",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Ascend slowly",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ascending slowly is the best way to avoid AMS. Some experts recommend the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If you live below 5000 feet (1500 meters), avoid ascending rapidly. On the first night, avoid sleeping above 9000 feet (2800 meters).",
"      </li>",
"      <li>",
"       If you plan to travel above 9800 feet (3000 meters), do not ascend more than 1600 feet (500 meters) per day as you go higher. Plan a day of rest for every 3200 feet (1000 meters) you ascend. On this rest day, do not ascend higher and do not over-exert yourself.",
"      </li>",
"      <li>",
"       Climb high and sleep low. Hike to a higher altitude during the day and return to a lower elevation to sleep at night. This will help you adjust to the altitude.",
"      </li>",
"      <li>",
"       If you plan to ski, hike, or climb, do not over-exert yourself during the first few days at altitude. Avoid alcohol and sleeping pills, especially as you are adjusting to the altitude in the first two days.",
"      </li>",
"      <li>",
"       Staying or hiking at elevations above 4900 feet (1500 meters) in the weeks before you ascend may allow you to ascend faster.",
"      </li>",
"      <li>",
"       If you drink caffeine (coffee, tea, soda) regularly, do not stop drinking it before or during your trip. Caffeine is safe at high altitudes, and stopping it suddenly can cause symptoms similar to AMS.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These suggestions are particularly important if you have had AMS or another high altitude illness previously. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"      \"High altitude illness: Physiology, risk factors, and general prevention\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Consider taking a preventive medicine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Preventive treatment with a medicine may be recommended if you have had high altitude illness previously or if you must ascend quickly. (See",
"     <a class=\"local\" href=\"#H10\">",
"      'AMS treatment'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     If you have had high altitude illness before, you may be able to avoid taking preventive medicines by ascending slowly. You will need a prescription for these treatments.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Prevention usually includes a medicine called acetazolamide, which you start taking the day before you ascend and continue for 48 hours or until you reach the highest point of your trip. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link\">",
"        \"Acute mountain sickness and high altitude cerebral edema\"",
"       </a>",
"       .)",
"       <br/>",
"       <br/>",
"       Acetazolamide can temporarily cause carbonated drinks to taste unpleasant. Other side effects can include the need to urinate more frequently, numbness or tingling in the hands or feet, nausea, drowsiness, or blurry vision. Acetazolamide is not recommended for pregnant women.",
"       <br/>",
"       <br/>",
"       Acetazolamide is a sulfa medicine, but many people with a sulfa allergy can take acetazolamide without a problem. If you are allergic to sulfa, talk to your doctor or nurse to determine if you should take a test dose before traveling [",
"       <a class=\"abstract\" href=\"UTD.htm?4/19/4403/abstract/1\">",
"        1",
"       </a>",
"       ]. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23594?source=see_link&amp;anchor=H20#H20\">",
"        \"Sulfonamide allergy in non HIV-infected patients\", section on 'Cross-reactivity'",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Dexamethasone is a steroid that may be recommended as a preventive treatment if you are allergic to acetazolamide.",
"      </li>",
"      <li>",
"       Taking aspirin or ibuprofen can help to prevent the headache that often occurs with AMS. If you will be ascending quickly, you can start taking aspirin or ibuprofen before you ascend. Otherwise, take it only if you develop a headache.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      AMS symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;The symptoms of AMS are similar to a hangover, and include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Headache",
"      </li>",
"      <li>",
"       Feeling tired",
"      </li>",
"      <li>",
"       Lightheadedness",
"      </li>",
"      <li>",
"       Lack of appetite",
"      </li>",
"      <li>",
"       Difficulty staying asleep (waking frequently)",
"      </li>",
"      <li>",
"       Nausea, sometimes with vomiting",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These symptoms may be mild or severe. AMS symptoms are often the worst after the first night and improve within one day if you do not ascend to a higher altitude. Symptoms may return as you travel higher. However, symptoms can sometimes persist for weeks, even if you do not climb higher.",
"    </p>",
"    <p>",
"     If you develop signs of acute mountain sickness, you should NOT climb higher until your symptoms have resolved (usually within 24 hours). You should rest and avoid drinking alcohol and taking sedatives or sleeping pills as you recover.",
"    </p>",
"    <p>",
"     This may mean that you, as well as your fellow climbers, will be delayed or unable to climb as high or as far as you had hoped. However, climbing higher while you have symptoms of AMS can lead to serious complications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      AMS treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;AMS treatment includes rest, descent, and may also include medicines to relieve symptoms. You should not exercise or climb higher until your symptoms have resolved. You should also know when and if you need to seek help. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'When to seek help'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Headache &ndash; You can take non-prescription medicines for headache, such as aspirin, acetaminophen (brand name: Tylenol&reg;), or ibuprofen (sample brand names: Advil&reg;, Motrin&reg;).",
"      </li>",
"      <li>",
"       Nausea or vomiting &ndash; If you have nausea or vomiting, a prescription medicine such as promethazine (brand name: Phenergan&reg;) or ondansetron (brand name: Zofran&reg;) may be helpful, if it is available.",
"      </li>",
"      <li>",
"       Descent &ndash; If your symptoms do not improve or worsen over 24 to 48 hours, descend to an altitude where you feel better. Most people feel better after descending 1600 to 3300 feet (500 to 1000 meters).",
"      </li>",
"      <li>",
"       Oxygen &ndash; If needed, treatment with inhaled oxygen can reduce the symptoms of AMS. You can use oxygen for a period of time (eg, one hour), only when you have symptoms, or while sleeping.",
"      </li>",
"      <li>",
"       Acetazolamide &ndash; Acetazolamide is a prescription medicine that you can take to treat and prevent AMS.",
"      </li>",
"      <li>",
"       Dexamethasone &ndash; Dexamethasone is a steroid that can reduce symptoms of AMS. You can take dexamethasone with acetazolamide, if needed. Dexamethasone increases blood sugar levels in people with diabetes.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      When to seek help",
"     </span>",
"     &nbsp;&mdash;&nbsp;AMS symptoms should improve as you adjust to the altitude, usually within 24 to 48 hours. If your symptoms worsen at any point, you should descend and seek help.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      HIGH ALTITUDE CEREBRAL EDEMA",
"     </span>",
"    </p>",
"    <p>",
"     High altitude cerebral edema (HACE) is a rare life-threatening altitude disease, and is a severe form of AMS. It is caused by leaky capillaries in the brain, which causes swelling.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      HACE prevention",
"     </span>",
"     &nbsp;&mdash;&nbsp;HACE can be prevented with the measures discussed above. (See",
"     <a class=\"local\" href=\"#H6\">",
"      'AMS prevention'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      HACE symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;HACE usually occurs within 1 to 3 days after traveling above 9,800 (3,000 meters). Symptoms may include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Exhaustion, drowsiness, and severe weakness",
"      </li>",
"      <li>",
"       Difficulty walking straight",
"      </li>",
"      <li>",
"       Confusion and irritability",
"      </li>",
"      <li>",
"       Acting drunk",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      HACE treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;HACE is a medical emergency and you should descend to a lower altitude as soon as possible. Waiting to descend can be disastrous; symptoms can worsen quickly and you may not be able to walk. Delaying descent increases the risk of life-threatening complications, or even death. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link\">",
"      \"Acute mountain sickness and high altitude cerebral edema\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Besides descent, other HACE treatments include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Several hours in a portable hyperbaric chamber. This can be a useful and life-saving treatment until descent is possible. (See",
"       <a class=\"local\" href=\"#H16\">",
"        'Portable hyperbaric chamber'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Dexamethasone. This is an important medicine to have on hand if you plan to sleep above 9,800 feet (3,000 meters). You should take it immediately if you develop signs of HACE, with the recommended dose being 8 to 10 mg by mouth. You should take 4 mg every six hours thereafter until you have descended. You should take dexamethasone before entering a hyperbaric chamber.",
"      </li>",
"      <li>",
"       You should use oxygen if it is available. You can use oxygen inside a hyperbaric chamber.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Portable hyperbaric chamber",
"     </span>",
"     &nbsp;&mdash;&nbsp;Portable hyperbaric chambers are inflatable pressure bags that can be used to treat people with acute mountain sickness, high altitude cerebral edema, or high altitude pulmonary edema. You are zipped into the chamber and the device is inflated with a foot pump (",
"     <a class=\"graphic graphic_picture graphicRef59691 \" href=\"UTD.htm?21/23/21872\">",
"      picture 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     When inflated, the air inside the chamber is more like the air you breathe at lower altitudes. This increases the amount of oxygen in your blood, relieving symptoms of high altitude illness quickly. You can remain in the chamber for several hours.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      HIGH ALTITUDE PULMONARY EDEMA",
"     </span>",
"    </p>",
"    <p>",
"     High altitude pulmonary edema (HAPE) is a potentially fatal condition in which lung capillaries leak and fluid accumulates in the lungs. HAPE is uncommon, but can occur in people who rapidly ascend to altitudes above 8200 feet (2500 meters).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      HAPE prevention",
"     </span>",
"     &nbsp;&mdash;&nbsp;As with other high altitude illnesses, the best way to prevent high altitude pulmonary edema (HAPE) is to ascend slowly. This is especially true if you have a previous history of HAPE.",
"    </p>",
"    <p>",
"     Preventive medicines are not usually recommended unless you have a history of HAPE and you must ascend quickly to altitudes above 8200 feet (2500 meters). Preventive medicines may include nifedipine (commonly used to treat high blood pressure), dexamethasone, or acetazolamide. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link\">",
"      \"High altitude pulmonary edema\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      HAPE symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Symptoms of HAPE include cough, breathlessness at rest or with activity, and difficulty walking uphill. These symptoms usually begin two to four days after arriving at altitude. You may or may not also have symptoms of acute mountain sickness. (See",
"     <a class=\"local\" href=\"#H9\">",
"      'AMS symptoms'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     Symptoms can worsen, and you may feel more short of breath, even while resting. You may also begin to cough up pink, frothy sputum (spit).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      HAPE treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;HAPE is a medical emergency. You should seek medical care or descend as soon as possible if you develop symptoms. Waiting to descend can be disastrous; symptoms can worsen quickly and you may not be able to walk. Waiting also increases the risk of developing life-threatening complications, or even death. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link\">",
"      \"High altitude pulmonary edema\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Treatments for HAPE include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Descend or seek medical care at the first sign of HAPE.",
"      </li>",
"      <li>",
"       Supplemental oxygen; this is the most effective treatment and should be started as soon as possible. It should be continued until symptoms resolve. Oxygen may be life-saving if descent is not possible.",
"      </li>",
"      <li>",
"       Hyperbaric treatment may be used as an alternative to descent, if it is available. You can use oxygen inside a hyperbaric chamber. (See",
"       <a class=\"local\" href=\"#H16\">",
"        'Portable hyperbaric chamber'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Nifedipine or other medicines may be helpful if oxygen is not available and descent is not possible.",
"      </li>",
"      <li>",
"       Stay warm and avoid cold temperatures",
"      </li>",
"      <li>",
"       Rest; this includes not carrying a pack while descending.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194140551\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194140543\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/18/23842?source=see_link\">",
"      Patient information: Altitude sickness (including mountain sickness) (The Basics)",
"     </a>",
"    </p>",
"    <p>",
"     <br/>",
"     <strong>",
"     </strong>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194140566\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/22/33122?source=see_link\">",
"      Patient information: Supplemental oxygen on commercial airlines (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H194140592\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link\">",
"      Acute mountain sickness and high altitude cerebral edema",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16042?source=see_link\">",
"      High altitude, air travel, and heart disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"      High altitude illness: Physiology, risk factors, and general prevention",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link\">",
"      High altitude pulmonary edema",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23594?source=see_link\">",
"      Sulfonamide allergy in non HIV-infected patients",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       United States Center for Disease Control and Prevention",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://wwwn.cdc.gov/travel/yellowBookCh6-AltitudeIllness.aspx\">",
"      wwwn.cdc.gov/travel/yellowBookCh6-AltitudeIllness.aspx",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       International Society for Mountain Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ismmed.org/\">",
"      www.ismmed.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?4/19/4403/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?4/19/4403?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4403/abstract/1\">",
"      Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003; 349:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4403/abstract/2\">",
"      Schoene RB. Illnesses at high altitude. Chest 2008; 134:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4403/abstract/3\">",
"      Hackett PH, Roach RC. High-altitude illness. N Engl J Med 2001; 345:107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f4_19_4403=[""].join("\n");
var outline_f4_19_4403=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PREPARING TO TRAVEL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           ACUTE MOUNTAIN SICKNESS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           HIGH ALTITUDE CEREBRAL EDEMA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           HIGH ALTITUDE PULMONARY EDEMA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/23/21872\" title=\"picture 1\">",
"           Portable hyperbaric chamber",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f4_19_4404="Chlorzoxazone: Pediatric drug information";
var content_f4_19_4404=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorzoxazone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40532?source=see_link\">",
"    see \"Chlorzoxazone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/23/8564?source=see_link\">",
"    see \"Chlorzoxazone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lorzone&trade;;",
"     </li>",
"     <li>",
"      Parafon Forte&reg; DSC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Skeletal Muscle Relaxant, Nonparalytic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40532?source=see_link\">",
"      see \"Chlorzoxazone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 20 mg/kg/day or 600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 250-750 mg 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parafon Forte&reg; DSC: 500 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lorzone&trade;: 375 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lorzone&trade;: 750 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of muscle spasm and pain associated with acute musculoskeletal conditions",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F150780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F150778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, lightheadedness, paradoxical stimulation, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash (rare), petechiae (rare), ecchymoses (rare), angioedema (very rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, GI bleeding (rare), nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urine discoloration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis (very rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorzoxazone or any component; impaired liver function",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious (including fatal) hepatocellular toxicity has been reported rarely",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F150769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2A6 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May decrease the metabolism of Chlorzoxazone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Chlorzoxazone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1057312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Watercress may decrease chlorzoxazone clearance",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13277400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts on the spinal cord and subcortical levels of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining skeletal muscle spasms",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 3-4 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Readily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver by glucuronidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: &sim;60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Adults: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine as conjugates; &lt;1% excreted unchanged in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/23/8564?source=see_link\">",
"      see \"Chlorzoxazone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May color urine orange or purple-red; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; notify physician if experiencing fever, rash, anorexia, right upper quadrant pain, dark urine, or jaundice",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13151 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_19_4404=[""].join("\n");
var outline_f4_19_4404=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150751\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057304\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057298\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150735\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150722\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057307\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057306\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150780\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150778\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057311\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057297\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150769\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150730\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057312\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13277400\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057303\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057296\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057309\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057310\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057302\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13151\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13151|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40532?source=related_link\">",
"      Chlorzoxazone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/23/8564?source=related_link\">",
"      Chlorzoxazone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_19_4405="Eltrombopag: Patient drug information";
var content_f4_19_4405=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Eltrombopag: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"     see \"Eltrombopag: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6809750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Promacta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12817171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Revolade&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700734",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems. Call your doctor if you see dark urine, feel tired, are not hungry, have an upset stomach, are throwing up, or have yellowing of the skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4155546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the risk of liver failure when taken with interferon and ribavirin in patients with hepatitis C.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to raise platelet counts.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702015",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to eltrombopag or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had blood clots, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697127",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bone marrow health problem called myelodysplastic syndrome (MDS), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697193",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698499",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam before starting care and then one every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3378179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are of East Asian descent, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696878",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take dairy products, calcium, iron, magnesium, zinc, multivitamins with minerals, or antacids within 4 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care to stop injury and avoid falls or crashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697933",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cataracts with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bruising.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain in the upper, right side.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12169 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_19_4405=[""].join("\n");
var outline_f4_19_4405=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6809750\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12817171\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018240\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018242\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018241\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018246\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018247\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018249\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018244\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018245\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018250\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018251\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=related_link\">",
"      Eltrombopag: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_19_4406="Chronic eosinophilic pneumonia HRCT";
var content_f4_19_4406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F86464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F86464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic eosinophilic pneumonia HRCT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 595px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial (A) and coronal (B) high resolution computed tomography images from a patient with chronic eosinophilic pneumonia (CEP). The findings include bilateral, upper lobe predominant, and peripheral consolidative and ground-glass opacities. In CEP, lung involvement is bilateral 75 percent of the time and confined to the upper lobe in 50 percent. While these findings are \"classic\", it should be recognized that the chest imaging findings in most cases of CEP are not classic.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David A Lynch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_19_4406=[""].join("\n");
var outline_f4_19_4406=null;
var title_f4_19_4407="Management of premature rupture of the fetal membranes at term";
var content_f4_19_4407=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of premature rupture of the fetal membranes at term",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/19/4407/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4407/contributors\">",
"     William E Scorza, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/19/4407/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4407/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/19/4407/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4407/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/19/4407/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature rupture of the membranes (PROM) refers to rupture of the fetal membranes prior to the onset of regular uterine contractions. It may occur at term (&ge;37 weeks of gestation) or preterm (&lt;37 weeks of gestation); the latter is designated preterm PROM (PPROM). Midtrimester PROM typically refers to PPROM at 16 to 26 weeks of gestation; this is an arbitrary definition, which varies slightly among investigators. The frequencies of term, preterm, and midtrimester PROM are approximately 8, 3, and less than 1 percent of pregnancies, respectively.",
"   </p>",
"   <p>",
"    Management of PROM depends upon several factors, most importantly the gestational age at occurrence and the maternal-fetal clinical condition. The management of PROM at term will be reviewed here. Issues regarding midtrimester PROM and management of PPROM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27353?source=see_link\">",
"     \"Midtrimester preterm premature rupture of membranes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with term premature rupture of the membranes (PROM) should be evaluated by a clinician. Whether the patient should be evaluated immediately or can remain at home for a few hours to see if labor begins has not been studied. In the absence of high quality data supporting the safety of delaying evaluation, we feel the most prudent approach is prompt assessment to confirm membrane rupture, exclude the presence of infection or a nonreassuring fetal heart rate pattern, determine fetal position, evaluate maternal and fetal well-being, and discuss options for further management. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of PROM is based upon a characteristic history (ie, leaking fluid per vagina) and speculum examination (ie, visualization of fluid flowing from the cervical os), supplemented by diagnostic testing of fluid in the posterior fornix, if the diagnosis is uncertain. The clinical manifestations and diagnosis of PROM are the same across gestation and are discussed in detail separately. Digital cervicovaginal examination should be avoided, as it has been associated with an increased risk of intrauterine infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link&amp;anchor=H4#H4\">",
"       \"Preterm premature rupture of membranes\", section on 'Clinical manifestations and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gestational age is determined according to the usual parameters (last menstrual period",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ultrasound bi",
"1ff8",
"ometry). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=see_link\">",
"       \"Prenatal assessment of gestational age\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fetal well-being is evaluated with a nonstress test, with or without a biophysical profile. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=see_link\">",
"       \"Overview of fetal assessment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fetal position is determined by transabdominal physical examination (Leopold&rsquo;s maneuvers) and ultrasound examination, as needed.",
"     </li>",
"     <li>",
"      Maternal evaluation includes assessment for labor, infection (eg, fever, tachycardia, uterine tenderness), and medical and obstetrical complications. Laboratory studies are the same as those for women admitted with spontaneous labor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=see_link&amp;anchor=H6#H6\">",
"       \"Management of normal labor and delivery\", section on 'Evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACTIVE OR EXPECTANT MANAGEMENT?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key decision in management of uncomplicated term premature rupture of the membranes (PROM) is whether to initiate delivery or take an expectant approach. We suggest prompt delivery for women with term PROM. Labor is induced, unless there are contraindications to labor or vaginal delivery, in which case cesarean delivery is performed. Our approach is based on the increased risk of infection with expectant management, as well as a general preference for expedited delivery among outpatients. Other factors to consider are the risks of cord prolapse, cord compression, or abruption with expectant management, as well as the cost and length of hospitalization while waiting for labor to begin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/1\">",
"     1",
"    </a>",
"    ]. Women who choose induction need to be aware of the possibility of long labor, failure to progress, and cesarean delivery.",
"   </p>",
"   <p>",
"    For a patient who declines induction, we work with her to set a time limit for expectant management if she does not go into labor. Development of infection or other complications would be an indication for delivery by the most appropriate method for the clinical situation.",
"   </p>",
"   <p>",
"    A 2006 systematic review of 12",
"    <span class=\"nowrap\">",
"     randomized/quasi-randomized",
"    </span>",
"    trials of women with PROM at &ge;37 weeks of gestation compared pregnancy outcome of planned intervention versus expectant management and provides support for our approach [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/2\">",
"     2",
"    </a>",
"    ]. Compared with expectant management, planned intervention resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fewer maternal infections (chorioamnionitis: 6.8 versus 9.8 percent, RR 0.74, 95% CI 0.56-0.97, endometritis 2.3 versus 8.3 percent, RR 0.30, 95% CI 0.12-0.74). For every 50 women who undergo intervention, 1 case of chorioamnionitis would be avoided.",
"     </li>",
"     <li>",
"      Fewer neonatal intensive care unit admissions (12.6 versus 17.0 percent, RR 0.73, 95% CI 0.58-0.91), and a possible trend in reduction of neonatal infection (2.3 versus 2.9 percent, RR 0.83, 95% CI 0.61-1.12)",
"     </li>",
"     <li>",
"      No increase in the rate of cesarean delivery, even in patients with unfavorable cervixes (RR 0.97, 95% CI 0.69-1.37)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings were limited by heterogeneity among studies such that immediate induction included waiting 2 to 12 hours after membrane rupture while expectant management included no induction or induction 24 to 96 hours after membrane rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/3\">",
"     3",
"    </a>",
"    ]. The results were also dominated by one large trial (the term PROM study) from the TermPROM study group, which included over 5000 participants and comprised 70 percent of the total number of participants included in the review [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of statistical difference in neonatal infection rates between expectant and active&nbsp;management was likely due to underpowering, given that the other&nbsp;infection-related outcomes were significantly increased in the expectant management group.&nbsp;Even a small increase in risk of neonatal infection is important because, if severe (ie, sepsis), there is a small (&lt;5 percent) risk of death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26200?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment and outcome of sepsis in term and late preterm infants\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent studies have provided additional support for prompt intervention. In one such study, the rates of chorioamnionitis and endometritis at term significantly increased after 12 and 16 hours, respectively: chorioamnionitis 2.7 percent before 12 hours versus 11.8 percent after 12 hours (multivariate analysis OR 2.3, 95% CI 1.2-4.4) and endometritis 1.0 percent before 16 hours versus 3.6 percent after 16 hours (multivariate analysis OR 2.5, 95% CI 1.1-5.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/5\">",
"     5",
"    </a>",
"    ]. The risk of postpartum hemorrhage increased significantly, as well (7.2 before eight hours versus 21.8 percent after eight hours; OR 2.8, 95% CI 1.1-7.2).",
"   </p>",
"   <p>",
"    In another large study, the rate of neonatal sepsis increased with duration of membrane rupture: 0.3 percent at 0 to 6 hours, 0.5 percent at 6 to 18 hours, 0.8 percent at 18 to 24 hours, and 1.1 percent after 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H883270\">",
"    <span class=\"h2\">",
"     Cost analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An economic analysis using data derived from the term PROM study compared all maternal and neonatal treatment costs associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    induction to costs associated with expectant management or induction with prostaglandins (prostaglandin E2 gel) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/7\">",
"     7",
"    </a>",
"    ]. In all of the economic models, induction with oxytocin was less expensive than the alternatives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H882368\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF INDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest induction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    , without preinduction cervical ripening. Meta-analyses of randomized trials have not demonstrated a clear benefit from initial use of any prostaglandin in women with premature rupture of the membranes (PROM), including those with unfavorable cervixes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. Oxytocin is easier to titrate than prostaglandins, and may be less expensive, depending on the prostaglandin preparation. However, a clinician may still choose to use prostaglandins if the cervix is particularly unfavorable and",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    risk benefit&nbsp;assessment for an individual patient favors use of a cervical ripening agent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link\">",
"     \"Principles of labor induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    is inexpensive, readily available, can be administered intravaginally and is stable at room temperature. For these reasons, it has some advantage over other prostaglandin preparations. At least one randomized trial has demonstrated",
"1ff8",
" equivalent efficacy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    for induction of labor in term PROM [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/13\">",
"     13",
"    </a>",
"    ]. If misoprostol is chosen for ripening or induction, an initial dose of 25 mcg is placed in the posterior fornix and it can be repeated every three to six hours, depending on the maternal and fetal response. Alternatively, 50 mcg can be used, but caution is advised because the incidence of tachysystole is greater [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/14\">",
"     14",
"    </a>",
"    ]. At least one randomized trial has reported",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/38/13927?source=see_link\">",
"     dinoprostone",
"    </a>",
"    to be efficacious in patients with an unfavorable cervix with term PROM [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/15\">",
"     15",
"    </a>",
"    ]. A single dose of dinoprostone was administered vaginally for up to 12 hours followed by oxytocin infusion. The authors reported a significantly greater number of women delivering within 24 hours of induction and fewer failed inductions than when oxytocin was used alone.",
"   </p>",
"   <p>",
"    There is minimal information on the safety of mechanical methods of cervical ripening in PROM [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/16\">",
"     16",
"    </a>",
"    ]. For patients with intact membranes, a systematic review of randomized trials reported a significantly increased risk of maternal infection (eg, chorioamnionitis, endometritis) for \"all mechanical methods\" and for balloon catheters specifically [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/17\">",
"     17",
"    </a>",
"    ]. Neonatal infection rates were not increased. We suggest avoiding mechanical methods of cervical ripening in PROM, given these findings in a population at lower risk of infection than PROM patients and the generally good response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    induction in PROM patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41993?source=see_link&amp;anchor=H3#H3\">",
"     \"Techniques for ripening the unfavorable cervix prior to induction\", section on 'Mechanical methods'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EXPECTANT MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;After weighing the risks and benefits of induction versus expectant management (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Active or expectant management?'",
"    </a>",
"    above), women with otherwise uncomplicated pregnancies who are averse to intervention may reasonably choose to undergo a trial of expectant management. These women should have no contraindications to labor and vaginal delivery, no evidence of clinical chorioamnionitis or other medical or obstetrical complications, and reassuring fetal testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H884259\">",
"    <span class=\"h2\">",
"     Duration of expectant management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with term premature rupture of the membranes (PROM) who are followed expectantly go into spontaneous labor and deliver within 24, 48, and 72 hours of PROM in 70, 85, and 95 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/4,18\">",
"     4,18",
"    </a>",
"    ]. There are no strong data on which to base a recommendation for the maximum duration of expectant management in the absence of pregnancy complications. In the term PROM study, labor was induced if complications developed or spontaneous labor had not started by 96 hours post membrane rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/4\">",
"     4",
"    </a>",
"    ], and the risk of chorioamnionitis appeared to increase significantly after 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H883322\">",
"    <span class=\"h2\">",
"     Meconium stained amniotic fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with meconium stained amniotic fluid were excluded from the term PROM study [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/4\">",
"     4",
"    </a>",
"    ]. Meconium stained amniotic fluid has been associated with an increased risk of clinical chorioamnionitis and positive amniotic fluid cultures, nonreassuring intrapartum fetal heart rate patterns, and meconium aspiration syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. However, there is no evidence that immediate induction of labor will reduce the risk of these complications, thus meconium stained amniotic fluid is not a strong contraindication to expectant management if antepartum fetal assessment is otherwise reassuring. In some cases, meconium-like staining is actually pigment associated with decidual hemorrhage. Although there are no data from randomized trials, induction and continuous fetal monitoring are prudent when meconium is thick.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Expectant management in hospital or at home?",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest hospitalizing women with PROM. When the TermPROM study group compared outcomes of expectant management at home with expectant management in the hospital, women who were sent home were more likely to develop clinical chorioamnionitis (10.1 versus 6.4 percent; P = 0.006) and their neonates were more likely to be diagnosed with infection (3.1 versus 1.7 percent; P = 0.06) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/22\">",
"     22",
"    </a>",
"    ]. Multiple logistic regression analyses found that women managed at home compared with in hospital had a higher risk of neonatal infection (OR 1.97, 95% CI 1.00-3.90) and nulliparas managed at home were at increased risk of needing antibiotics before delivery (OR 1.52 95% CI 1.04-2.24). Another risk of home management is the possibility of rapid labor and delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who ask for home expectant management, one author proposed the following selection criteria to enhance safety [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cephalic presentation",
"     </li>",
"     <li>",
"      No intrauterine infection",
"     </li>",
"     <li>",
"      Reassuring fetal heart rate tracing",
"     </li>",
"     <li>",
"      Deepest amniotic fluid pocket on ultrasound &gt;2 cm",
"     </li>",
"     <li>",
"      Initial inpatient observation for 72 hours with antibiotic prophylaxis",
"     </li>",
"     <li>",
"      Reliable patient",
"     </li>",
"     <li>",
"      Assistance at home",
"     </li>",
"     <li>",
"      Dependable transportation",
"     </li>",
"     <li>",
"      Home located within 20 minutes of the hospital",
"     </li>",
"     <li>",
"      Ability to check pulse and temperature every six hours, with parameters for notifying their clinician (eg, pulse &gt;100, temperature &ge;100 &deg;Fahrenheit [37.8 &deg; Celsius])",
"     </li>",
"     <li>",
"      Daily fetal kick counts",
"     </li>",
"     <li>",
"      Nonstress test and leukocyte count twice weekly",
"     </li>",
"     <li>",
"      Weekly ultrasound examination",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analysis of randomized trials supports the use of antibiotic prophylaxis in preterm PROM (PPROM) to reduce the frequency of maternal and fetal infection and delay the onset of preterm labor (ie, prolong latency). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=see_link&amp;anchor=H17#H17\">",
"     \"Preterm premature rupture of membranes\", section on 'Antibiotics'",
"    </a>",
"    .) Prolonging latency is not a goal in term PROM, but minimizing maternal-fetal infection remains important. There is sparse evidence on the effects of",
"1ff8",
" antibiotic prophylaxis with term PROM. A 2002 meta-analysis included only two trials involving a total of 838 women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/25\">",
"     25",
"    </a>",
"    ]. Compared to placebo or no treatment, use of prophylactic antibiotics resulted in a statistically significant reduction in endometritis (RR 0.09, 95% CI 0.01-0.73), but no significant reduction in chorioamnionitis or neonatal mortality or morbidity (eg, infection, pneumonia, meningitis, mechanical ventilation). A subsequent randomized trial of antibiotic prophylaxis (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    ) versus no antibiotic prophylaxis also reported that antibiotics decreased chorioamnionitis, but did not lead to a significant reduction in neonatal infection rates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/26\">",
"     26",
"    </a>",
"    ]. These data are not sufficient to make a strong recommendation for or against use of prophylactic antibiotics in expectantly managed patients at term.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Group B streptococcus colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive screening culture for group B streptococcus (GBS) does not necessarily preclude expectant management; there is no consensus on the safety of expectant management in these women [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/1\">",
"     1",
"    </a>",
"    ]. We agree with Centers for Disease Control (CDC) guidelines that maternal prophylaxis against early onset neonatal GBS disease should be administered for 48 hours after PROM and intrapartum to women with positive GBS cultures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link&amp;anchor=H9#H9\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\", section on 'Indications for antibiotic prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link&amp;anchor=H15#H15\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\", section on 'Preterm premature rupture of membranes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a secondary analysis, the term PROM study evaluated the effect of induction of labor on neonatal infection in mothers with PROM who were GBS positive [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/27\">",
"     27",
"    </a>",
"    ]. Induction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    was associated with a lower rate of neonatal infection than expectant management (2.5 percent versus &gt;8 percent). However, prenatal GBS culture and chemoprophylaxis were performed at the discretion of the provider, which limits the generalizability of these results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H884179\">",
"    <span class=\"h2\">",
"     Maternal and fetal monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no standards for maternal-fetal monitoring in expectantly managed term PROM and no data from randomized trials on which to base recommendations. There is consensus that digital vaginal examination and vaginal intercourse should be avoided to reduce the risk of intrauterine infection. Some type of fetal surveillance is reasonable (eg, kick counts, nonstress tests, biophysical profile) to provide the clinician and patient with some assurance of fetal well-being, but none of these tests has good sensitivity for predicting fetal infection, even when performed daily. However, cord prolapse or cord compression may be first suspected because of fetal heart rate decelerations.",
"   </p>",
"   <p>",
"    In the term PROM study, women assigned to expectant management were asked to check their temperature twice daily and report temperatures &ge;37.5 Celsius, monitor and report changes in color or odor of amniotic fluid, and notify their clinician if any complications developed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4407/abstract/22\">",
"     22",
"    </a>",
"    ]. Other monitoring, such as white blood cell count, was at physician discretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1159563597\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE NEWBORN",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and diagnosis of sepsis in term and late preterm infants\", section on 'Maternal and neonatal risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premature rupture of the membranes (PROM) refers to rupture of the fetal membranes prior to the onset of labor or regular uterine contractions. It occurs in 8 percent of pregnancies at term. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial evaluation of all pregnancies in which PROM is suspected should include confirmation of membrane rupture, confirmation of gestational age, and assessment of fetal well-being. The need for group B streptococcal chemoprophylaxis should also be determined. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest prompt induction of labor in women with term PROM (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Compared to expectant management, induction of labor is associated with a reduction in infection and lower treatment costs, with no increase in cesarean delivery. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Active or expectant management?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest induction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Oxytocin is as effective as prostaglandins, is easier to titrate, and may be less expensive, depending on the preparation. (See",
"      <a class=\"local\" href=\"#H882368\">",
"       'Management of induction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Term PROM (C-Obs 36). July 2010. file://www.ranzcog.edu.au/the-ranzcog/policies-and-guidelines/college-statements/429-term-prom-c-obs-36-.html (Accessed on October 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/2\">",
"      Dare MR, Middleton P, Crowther CA, et al. Planned early birth versus expectant management (waiting) for prelabour rupture of membranes at term (37 weeks or more). Cochrane Database Syst Rev 2006; :CD005302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/3\">",
"      Mozurkewich EL, Wolf FM. Premature rupture of membranes at term: a meta-analysis of three management schemes. Obstet Gynecol 1997; 89:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/4\">",
"      Hannah ME, Ohlsson A, Farine D, et al. Induction of labor compared with expectant management for prelabor rupture of the membranes at term. TERMPROM Study Group. N Engl J Med 1996; 334:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/5\">",
"      Tran SH, Cheng YW, Kaimal AJ, Caughey AB. Length of rupture of ",
"1ff8",
"membranes in the setting of premature rupture of membranes at term and infectious maternal morbidity. Am J Obstet Gynecol 2008; 198:700.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/6\">",
"      Herbst A, K&auml;ll&eacute;n K. Time between membrane rupture and delivery and septicemia in term neonates. Obstet Gynecol 2007; 110:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/7\">",
"      Gafni A, Goeree R, Myhr TL, et al. Induction of labour versus expectant management for prelabour rupture of the membranes at term: an economic evaluation. TERMPROM Study Group. Term Prelabour Rupture of the Membranes. CMAJ 1997; 157:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/8\">",
"      Tan BP, Hannah ME. Prostaglandins versus oxytocin for prelabour rupture of membranes at term. Cochrane Database Syst Rev 2000; :CD000159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/9\">",
"      Lin MG, Nuthalapaty FS, Carver AR, et al. Misoprostol for labor induction in women with term premature rupture of membranes: a meta-analysis. Obstet Gynecol 2005; 106:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/10\">",
"      Hofmeyr GJ, G&uuml;lmezoglu AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev 2010; :CD000941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/11\">",
"      Kelly AJ, Malik S, Smith L, et al. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database Syst Rev 2009; :CD003101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/12\">",
"      Crane JM, Young DC. Induction of labour with a favourable cervix and/or pre-labour rupture of membranes. Best Pract Res Clin Obstet Gynaecol 2003; 17:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/13\">",
"      Zetero��lu S, Engin-Ust&uuml;n Y, Ust&uuml;n Y, et al. A prospective randomized study comparing misoprostol and oxytocin for premature rupture of membranes at term. J Matern Fetal Neonatal Med 2006; 19:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/14\">",
"      ACOG Committee on Practice Bulletins -- Obstetrics. ACOG Practice Bulletin No. 107: Induction of labor. Obstet Gynecol 2009; 114:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/15\">",
"      G&uuml;ng&ouml;rd&uuml;k K, Asicioglu O, Besimoglu B, et al. Labor induction in term premature rupture of membranes: comparison between oxytocin and dinoprostone followed 6 hours later by oxytocin. Am J Obstet Gynecol 2012; 206:60.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/16\">",
"      Wolff K, Swahn ML, Westgren M. Balloon catheter for induction of labor in nulliparous women with prelabor rupture of the membranes at term. A preliminary report. Gynecol Obstet Invest 1998; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/17\">",
"      Heinemann J, Gillen G, Sanchez-Ramos L, Kaunitz AM. Do mechanical methods of cervical ripening increase infectious morbidity? A systematic review. Am J Obstet Gynecol 2008; 199:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/18\">",
"      Keirse MJ, Ottervanger HP, Smit W. Controversies: prelabor rupture of the membranes at term: the case for expectant management. J Perinat Med 1996; 24:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/19\">",
"      Seaward PG, Hannah ME, Myhr TL, et al. International Multicentre Term Prelabor Rupture of Membranes Study: evaluation of predictors of clinical chorioamnionitis and postpartum fever in patients with prelabor rupture of membranes at term. Am J Obstet Gynecol 1997; 177:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/20\">",
"      Romero R, Hanaoka S, Mazor M, et al. Meconium-stained amniotic fluid: a risk factor for microbial invasion of the amniotic cavity. Am J Obstet Gynecol 1991; 164:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/21\">",
"      Seaward PG, Hannah ME, Myhr TL, et al. International multicenter term PROM study: evaluation of predictors of neonatal infection in infants born to patients with premature rupture of membranes at term. Premature Rupture of the Membranes. Am J Obstet Gynecol 1998; 179:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/22\">",
"      Hannah ME, Hodnett ED, Willan A, et al. Prelabor rupture of the membranes at term: expectant management at home or in hospital? The TermPROM Study Group. Obstet Gynecol 2000; 96:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/23\">",
"      Ellestad SC, Swamy GK, Sinclair T, et al. Preterm premature rupture of membrane management--inpatient versus outpatient: a retrospective review. Am J Perinatol 2008; 25:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/24\">",
"      Bartfield MC, Carlan SJ. The home management of preterm premature ruptured membranes. Clin Obstet Gynecol 1998; 41:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/25\">",
"      Flenady V, King J. Antibiotics for prelabour rupture of membranes at or near term. Cochrane Database Syst Rev 2002; :CD001807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/26\">",
"      Passos F, Cardoso K, Coelho AM, et al. Antibiotic prophylaxis in premature rupture of membranes at term: a randomized controlled trial. Obstet Gynecol 2012; 120:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4407/abstract/27\">",
"      Hannah ME, Ohlsson A, Wang EE, et al. Maternal colonization with group B Streptococcus and prelabor rupture of membranes at term: the role of induction of labor. TermPROM Study Group. Am J Obstet Gynecol 1997; 177:780.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6757 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-218.28.111.102-8C7B610DBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_19_4407=[""].join("\n");
var outline_f4_19_4407=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a 15a4 class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACTIVE OR EXPECTANT MANAGEMENT?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H883270\">",
"      Cost analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H882368\">",
"      MANAGEMENT OF INDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EXPECTANT MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H884259\">",
"      Duration of expectant management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H883322\">",
"      Meconium stained amniotic fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Expectant management in hospital or at home?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Group B streptococcus colonization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H884179\">",
"      Maternal and fetal monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1159563597\">",
"      MANAGEMENT OF THE NEWBORN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=related_link\">",
"      Clinical features and diagnosis of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33114?source=related_link\">",
"      Management of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27353?source=related_link\">",
"      Midtrimester preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=related_link\">",
"      Overview of fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41993?source=related_link\">",
"      Techniques for ripening the unfavorable cervix prior to induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26200?source=related_link\">",
"      Treatment and outcome of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_19_4408="Uterine perforation during gynecologic procedures";
var content_f4_19_4408=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Uterine perforation during gynecologic procedures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/19/4408/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4408/contributors\">",
"     Barbara S Levy, MD, PS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/19/4408/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4408/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/19/4408/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4408/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/19/4408/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine perforation is a potential complication of all intrauterine procedures and may be associated with injury to surrounding blood vessels or viscera (bladder, bowel) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In addition, uterine perforations and associated complications that are not diagnosed at the time of the procedure can result in hemorrhage or sepsis. The risk of uterine perforation is increased by factors that make access to the endometrial cavity difficult (eg, cervical stenosis) or alter the strength of the myometrial wall (eg, pregnancy, menopause).",
"   </p>",
"   <p>",
"    The prevention, diagnosis, and management of uterine perforation during gynecologic procedures will be reviewed here. Other complications of uterine surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24631?source=see_link\">",
"     \"Complications of gynecologic surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link\">",
"     \"Overview of hysteroscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link\">",
"     \"Overview of pregnancy termination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Uterine perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of the incidence of uterine perforation are generally based upon self-report by surgeons. In addition, many perforations are not recognized or confirmed, so it is likely that any reported incidence is an underestimate.",
"   </p>",
"   <p>",
"    In most studies, hysteroscopy is complicated by confirmed uterine perforation in approximately 1 percent of operative procedures. There are fewer perforations during diagnostic hysteroscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link&amp;anchor=H38#H38\">",
"     \"Overview of hysteroscopy\", section on 'Uterine perforation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During dilation and curettage for disorders not related to pregnancy, perforation has been reported in approximately 0.3 percent of premenopausal patients and 2.6 percent in the postmenopausal patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35480?source=see_link&amp;anchor=H21#H21\">",
"     \"Dilation and curettage\", section on 'Uterine perforation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For pregnancy-related procedures, the risk of perforation is increased. It is most common when attempting control of postpartum hemorrhage after a third trimester delivery (as high as 5 percent). For both first and second trimester procedures (for induced or spontaneous abortion), the rate of uterine perforation is approximately 0.5 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of pregnancy termination\", section on 'Uterine perforation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endometrial ablation complicated by uterine perforation has been reported in approximately 1 percent of procedures; the rate is higher for endometrial resection (2 percent or higher). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link&amp;anchor=H34#H34\">",
"     \"An overview of endometrial ablation\", section on 'Uterine perforation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Uterine perforation can also occur in office-based procedures, including intrauterine device insertion and endometrial biopsy. The relevant data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19898?source=see_link\">",
"     \"Management of problems related to intrauterine contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/131?source=see_link\">",
"     \"Endometrial sampling procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Associated hemorrhage or visceral injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few studies regarding the proportion of uterine perforations that result in hemorrhage or injury to surrounding structures. Data from three of the largest series include a total of 92 uterine perforations complicated by 16 cases of hemorrhage and 6 injuries to bowel or bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine perforation occurs most often during mechanical cervical dilation or insertion of a sharp uterine instrument [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Factors that make access to the endometrial cavity difficult or alter the strength of the myometrial wall predispose to uterine perforation, including [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cervical stenosis",
"     </li>",
"     <li>",
"      Distortion or scarring of the endocervical canal (eg, due to cone biopsy)",
"     </li>",
"     <li>",
"      Uterine malposition (eg, extreme retroversion or retroflexion)",
"     </li>",
"     <li>",
"      Distortion of uterine anatomy (eg, due to fibroids, intrauterine adhesions)",
"     </li>",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      Menopausal endometrial atrophy and myometrial thinning.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a lack of surgical experience, extensive operative procedures (eg, resection of fibroids or intrauterine adhesions), and, for pregnancy-related procedures, underestimation of gestational age, have been associated with a higher risk of uterine perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/3,5,9-11\">",
"     3,5,9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pre-procedure preparation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are planning a procedure that involves intrauterine instrumentation should be counseled about the risk of uterine perforation and, if perforation should occur, the possibility of additional procedures (laparoscopy or laparotomy). This discussion should be documented on the procedure consent form and in the medical record. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\", section on 'Informed consent and patient expectations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Pre-procedure evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for uterine perforation may be suggested or confirmed during the pre-procedure history and physical examination. As an example, women with potential cervical stenosis include those who have never had a vaginal delivery and postmenopausal women. Similarly, there is a high risk for abnormalities of the endocervical canal in women who have had surgical procedures involving the cervix including loop electrosurgical excision procedure, cervical conization, and cerclage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=see_link&amp;anchor=H23#H23\">",
"     \"Congenital cervical anomalies and benign cervical lesions\", section on 'Cervical stenosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/17/33048?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Procedures for cervical conization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For procedures that are performed under local or no anesthesia, in our experience, endometrial access may be difficult in women with anxiety and resultant severe levator ani muscle tension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cervical preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical preparation, particularly in women at high risk of uterine perforation (eg, cervical stenosis, postmenopausal), may facilitate mechanical dilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    insertion of instruments into the uterine cavity. This can be accomplished with a prostaglandin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    ) or osmotic dilators (laminaria).",
"   </p>",
"   <p>",
"    In premenopausal women undergoing hysteroscopy, a systematic review of 10 randomized trials found that pre-procedure",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    was associated with a reduced need for further cervical dilation and a lower rate of cervical laceration. Rate of uterine perforation was not assessed, likely due to the low frequency of this complication.",
"   </p>",
"   <p>",
"    In postmenopausal women, randomized trials of pre-hysteroscopy",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    and the need for mechanical cervical dilation have yielded inconsistent results regarding the need for subsequent mechanical dilation; however, intraoperative pain is decreased.",
"   </p>",
"   <p>",
"    Cervical preparation for gynecologic procedures is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of hysteroscopy\", section on 'Cervical preparation and dilation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of pregnancy termination\", section on 'Cervical preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Preventive measures during the procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine perforation commonly occurs during cervical dilation or insertion of a sharp operative instrument [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/3-7\">",
"     3-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Uterine position",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perforation may result if cervical dilators are placed in the incorrect axis or with excessive force. Prior to beginning the procedure, a pelvic bimanual examination should be performed with careful attention to the uterine position to facilitate accurate placement of dilators. In obese women, a rectovaginal examination may be needed to accurately determine if significant flexion of the uterus is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42681?source=see_link&amp;anchor=H25#H25\">",
"     \"The gynecologic history and pelvic examination\", section on 'Bimanual examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Straightening the uterine axis will also facilitate placement of cervical dilators and other instruments through the endocervical canal into the uterus. This can be accomplished by placing a tenaculum on the anterior lip of the cervix and using gentle traction. An intracervical or paracervical block or regional or general anesthesia may be required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40439?source=see_link\">",
"     \"Pudendal and paracervical block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of hysteroscopy\", section on 'Anesthesia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Difficult cervical dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Difficult cervical dilation can also be approached by using smaller instruments for dilation (eg, lacrimal duct probe or urologic dilators).",
"   </p>",
"   <p>",
"    If the cervix cannot be dilated using gentle force, ultrasound guidance may be required to safely dilate the cervix and gain passage into the endometrial cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/12\">",
"     12",
"    </a>",
"    ]. There are no data evaluating this approach, but we find it useful in our clinical practice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35480?source=see_link&amp;anchor=H14#H14\">",
"     \"Dilation and curettage\", section on 'Cervical dilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, intracervical injection of dilute vasopressin (4 units per 80 mL normal saline) has been reported to facilitate cervical dilation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/13\">",
"     13",
"    </a>",
"    ]. Although generally well tolerated, vasopressin injection must be performed with caution, since intravascular injection or absorption has been associated with profound hypertension, bradycardia, and intraoperative mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/14\">",
"     14",
"    </a>",
"    ]. Due to this rare, but serious, complication, vasopressin injection is not recommended in the office setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of hysteroscopy\", section on 'Cervical preparation and dilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Safe use of operative instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safe use of transcervical instruments that are passed blindly depends upon knowledge of uterine position and use of appropriate pressure, as noted in the preceding sections. The ability to directly visualize hysteroscopic instruments allows for additional safety measures. As an example, a resectoscopic loop should always be moved towards the operator, and not pushed into the uterine wall [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/15\">",
"     15",
"    </a>",
"    ]. Also, energy sources should not be activated unless there is a clear view of the instrument.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PERIOPERATIVE PRESENTATION OF UTERINE PERFORATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     During the procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine perforation can be diagnosed during the perioperative period by direct visualization during the procedure or based on clinical signs of visceral or vascular injury. In addition, perforation should be suspected when a uterine sound, dilator, or operating instrument passes beyond the expected length of the uterus. The most common site of uterine perforation is the fundus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/8,16\">",
"     8,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perforation at the fundus is most common and typically leads to minimal bleeding, whereas a lateral uterine perforation may lacerate uterine blood vessels, thus resulting in immediate and profuse hemorrhage and, possibly, a broad ligament hematoma. A low cervical perforation can lacerate the descending branch of the uterine artery, which also can present with delayed cervical bleeding if the artery initially goes into spasm.",
"   </p>",
"   <p>",
"    During hysteroscopy, signs of possible injury to the myometrium include excessive bleeding from the uterus, sudden loss of visualization, sudden loss of uterine distension, and an abrupt increase in the distending fluid deficit. Any of these signs should prompt a careful search for perforation.",
"   </p>",
"   <p>",
"    Direct visualization of any of the following confirms a uterine perforation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A hole in the uterine wall is directly visualized via hysteroscopy, laparoscopy, or laparotomy",
"     </li>",
"     <li>",
"      Omentum (or other adipose tissue) or bowel is visible through an opening in the myometrium, or is present in the endometrial cavity or in a suction instrument (",
"      <a class=\"graphic graphic_figure graphicRef69249 \" href=\"UTD.htm?40/7/41074\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adipose tissue is identified in a curettage specimen by direct visualization by the surgeon or pathologist. Adipose tissue is present in the peritoneal cavity, but not within the uterus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of direct visualization of an opening or concern based on passage of an instrument beyond the fundal length, uterine perforation should be suspected if there are signs of visceral or vascular injury. These include excessive bleeding, hypotension, or acute onset of hematuria. Occult retroperitoneal or intraabdominal hemorrhage can also occur, with perioperative hypotension the first sign of a complication.",
"   </p>",
"   <p>",
"    If a perforation is suspected during the procedure, the procedure should be immediately halted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Post-procedure clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine perforation is generally recognized during the procedure. However, a patient with the following signs or symptoms after an intrauterine procedure should be evaluated for uterine perforation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe or persistent pelvic or abdominal pain",
"     </li>",
"     <li>",
"      Abdominal distension",
"     </li>",
"     <li>",
"      Heavy or persistent vaginal bleeding",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Hematuria",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many women experience mild to moderate cramping for several hours after a uterine procedure. However, severe or persistent abdominal pain is unusual and requires prompt evaluation. One series of 15 women who developed uterine perforations at second trimester dilatation and evacuation reported that unexpected pain was the most prominent sign [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/17\">",
"     17",
"    </a>",
"    ]. The pain may be focal or diffuse since its source may be a specific injury to the uterus, bowel, or bladder.",
"   </p>",
"   <p>",
"    Bowel may be perforated or become incarcerated in the uterine defect [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients with bowel injuries may not develop symptoms for several hours. Such injuries should be suspected if a patient has abdominal distension or continues to have abdominal pain, especially in the presence of tachycardia. Patients with bowel injury rarely present with rectal bleeding. Unrecognized bowel injury can be rapidly fatal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A uterine perforation that is not complicated by bleeding or injury to surrounding structures may require only observation, while a more involved perforation is a surgical emergency.",
"   </p>",
"   <p>",
"    If uterine perforation is suspected, the patient should be evaluated with vital signs and a pelvic and abdominal examination. If bleeding is suspected, laboratory evaluation includes a hematocrit and coagulation tests.",
"   </p>",
"   <p>",
"    Uterine perforation cannot be confirmed or excluded with any imaging study and thus imaging is not a routine part of the evaluation. In women with signs of hypovolemia without apparent bleeding, a pelvic ultrasound can be used to assess for a broad ligament or retroperitoneal hematoma.",
"   </p>",
"   <p>",
"    If there is any concern for ureteral or bladder injury, the integrity of these structures can be easily assessed by the intravenous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    dye, which is rapidly cleared by the kidneys. In addition, a catheter or cystoscope can be introduced into the bladder to look for fresh blood from an intravesical hemorrhage or the actual perforation.",
"   </p>",
"   <p>",
"    If bowel injury is suspected, abdominal exploration is warranted for diagnosis and potential repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with suspected uterine perforation may be managed expectantly or with surgical exploration, depending upon the likelihood of hemorrhage or visceral injury.",
"   </p>",
"   <p>",
"    In our practice, we do not give prophylactic antibiotics for women with suspected uterine perforation. We treat with antibiotics only if clinical signs of infection are present (eg, endometritis, peritonitis). No studies have addressed this issue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Candidates for observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If uterine perforation is thought to have occurred during cervical dilation or with a blunt instrument with no suction or electrosurgical energy source, the risk of vascular or visceral injury is low and close observation may be sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. The patient should be monitored for signs of intraperitoneal hemorrhage (eg, hypotension, dropping hematocrit, increasing abdominal distension) or visceral injury (increasing abdominal pain or tenderness, abdominal distension).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Criteria for surgical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal exploration should be performed immediately if there are signs of severe uterine bleeding or vascular or visceral injury are suspected. As an example, vigorous vaginal bleeding should prompt a pelvic examination to exclude a cervical laceration, followed by abdominal exploration.",
"   </p>",
"   <p>",
"    If electrosurgical energy, morcellation, or suction curettage were utilized during the procedure and perforation is suspected, the potential for serious injury is increased. In such patients, immediate abdominal exploration should be performed.",
"   </p>",
"   <p>",
"    Any intrauterine device, tubal sterilization device, or other foreign body that has entered the peritoneal cavity should be removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Abdominal exploration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who require abdominal exploration, laparoscopy is preferred if the patient is stable since the risks of perioperative morbidity are lower. A meta-analysis of 27 randomized clinical trials comparing operative laparoscopy to laparotomy for benign gynecological conditions found the overall risk of minor complications (eg, fever, wound or urinary tract infection) was significantly lower in women undergoing laparoscopic procedures. In addition, recovery time is shorter after laparoscopy. However, it is difficult to evaluate the entire bowel at laparoscopy and an experienced operative laparoscopist is needed to accomplish both evaluation and repair using laparoscopic instruments. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of conventional gynecologic laparoscopic surgery\", section on 'Role of laparoscopy in gynecologic surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laparotomy may be warranted in patients who are not hemodynamically stable. Once the abdomen has been entered, initial inspection should include identifying the site of uterine perforation and assessing for injury to adjacent structures.",
"   </p>",
"   <p>",
"    The patient should be kept in a stable position to avoid movement of bowel loops away from the area. Retaining the \"at risk\" loops of bowel in the pelvis will facilitate identification of injuries. Hemorrhage into the bowel wall or blanching of the bowel if energy sources were used may reflect bowel injury.",
"   </p>",
"   <p>",
"    Areas of brisk bleeding from the uterus or vessels should be controlled immediately. Bleeding from the uterine site can be stemmed using sutures or electrocoagulation. Large perforations (&gt;1 cm) should be reapproximated with suture. Depending on the site and extent of injury, resection of the perforated uterine segment may be necessary for repair [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/3\">",
"     3",
"    </a>",
"    ]. Failing these measures, hysterectomy may be needed; selective uterine artery embolization is an alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30408?source=see_link\">",
"     \"Interventional radiology in management of gynecological disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retroperitoneal injury may be difficult to recognize. The surgeon should look carefully for enlarging retroperitoneal hematoma formation.",
"   </p>",
"   <p>",
"    If injury to the bowel, bladder, or major vessels has occurred, consultation with a general surgeon, vascular surgeon",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a urologist is helpful when determining the extent of, and repairing, the injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Completing the original procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;If uterine perforation occurs with a blunt instrument with no suction or electrosurgical energy source, the original procedure can be completed under ultrasound guidance (also without use of suction or an energy source) and the woman can be observed.",
"   </p>",
"   <p>",
"    Another option is to complete the procedure under laparoscopic guidance. Laparoscopy allows for direct visualization of the perforation site and retraction of surrounding structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Post-procedure monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with uterine perforation will likely experience mild cramping or light bleeding.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    or nonsteroidal antiinflammatory drugs are usually adequate for postoperative pain control, if necessary.",
"   </p>",
"   <p>",
"    The patient should be advised to call her clinician if pain is severe or persistent, vaginal bleeding is heavy, or there are other symptoms of ongoing complications of uterine perforation (eg, hematuria, abdominal distension, fever). Delayed presentation of bowel perforation following unrecognized uterine perforation has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/19\">",
"     19",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H18\">",
"     'Post-procedure clinical manifestations'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The patient may resume most normal activities within 24 hours and should follow standard postoperative instructions for gynecologic procedures. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=see_link\">",
"     \"Patient information: Care after gynecologic surgery (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We see patients for a follow-up visit one week following the procedure to assess for further complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DELAYED PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine perforation should be suspected in women who have undergone an intrauterine procedure in the preceding three weeks and who present with symptoms of visceral or vascular injury, although such complications can also occur without uterine perforation (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Post-procedure clinical manifestations'",
"    </a>",
"    above). Some complications, including bowel injury, can present as late as three weeks after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with delayed diagnosis of uterine perforation typically present with an associated complication (eg, anemia, peritonitis) and need evaluation for the presenting complication rather than confirmation of the uterine perforation itself. Women who present after an intrauterine procedure with nonspecific abdominal pain with no signs of hemorrhage or visceral injury do not need to be evaluated for uterine perforation, although the possibility of perforation and visceral injury must always be considered when approaching these patients.",
"   </p>",
"   <p>",
"    Hemorrhage due to uterine perforation is likely to present perioperatively and, thus, be recognized before the patient leaves the hospital or clinic. This may result from severe injury to the uterine wall or a blood vessel. On the other hand, patients with occult retroperitoneal or intraabdominal bleeding (eg, a slowly expanding retroperitoneal hematoma) may not become symptomatic until several hours after a procedure.",
"   </p>",
"   <p>",
"    Visceral perforation can present either acutely or hours to weeks post-procedure. Fever, in particular, is a delayed sign that may result from an infection of the reproductive organs (eg, tubo-ovarian abscess), bowel, or urinary tract (eg, peritonitis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a complication associated with uterine perforation is suspected, the patient should be evaluated with vital signs and a pelvic and abdominal examination. If bleeding is suspected, laboratory evaluation includes a hematocrit and coagulation tests. If peritonitis or urinary tract infection is suspected, a white blood cell count and urine or blood cultures are also collected.",
"   </p>",
"   <p>",
"    Uterine perforation cannot be confirmed or excluded with any imaging study. In patients with anemia, fever,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pelvic mass or tenderness, pelvic ultrasound is the test of choice to identify a broad ligament or retroperitoneal hematoma or a tubo-ovarian abscess and can also exclude some other etiologies of pelvic pain. (See Tubo-ovarian abscess\", section on Imaging).",
"   </p>",
"   <p>",
"    If bowel or bladder injury are suspected, appropriate abdominal or urinary tract imaging should be performed. The evaluation of patients with suspected bowel or urinary tract injury is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnostic approach to abdominal pain in adults\", section on 'Acute abdominal pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18425?source=see_link&amp;anchor=H6#H6\">",
"     \"Blunt genitourinary trauma\", section on 'Primary evaluation and management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific complications should be treated as appropriate (eg, transfusion, antibiotic therapy, surgical repair of a perforated viscus). If abdominal exploration is performed, the uterus should be inspected for a perforation site. The absence of a visible defect does not exclude a previous uterine perforation, since small defects may have closed spontaneously subsequent to the procedure. However, if a uterine defect is visible, it should be closed to prevent future intraperitoneal infection or bowel incarceration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     EFFECTS ON FUTURE REPRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A uterine perforation, like any uterine incision, is likely to heal well. Adhesion formation is possible, however, no adverse effects of uterine perforation on fertility have been reported.",
"   </p>",
"   <p>",
"    Uterine perforation may weaken the uterine wall and raises concerns for an increased risk of uterine rupture during subsequent pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. The largest literature review regarding this issue identified 18 reports of uterine rupture in women who had a prior operative hysteroscopy, 10 of these women had a uterine perforation during the hysteroscopy; however, these women also had other risk factors for rupture (eg, extensive hysteroscopic resection of a septum or adhesions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electrosurgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4408/abstract/20\">",
"     20",
"    </a>",
"    ]. Further high quality studies are needed.",
"   </p>",
"   <p>",
"    We counsel women who have had a uterine perforation that there may be some elevated risk of uterine perforation in a subsequent pregnancy, but that the risk is likely minimal in the absence of other risk factors. We do not advise cesarean delivery for women with a uterine perforation who did not undergo a concurrent metroplasty, intrauterine adhesiolysis, or myomectomy and have not had a prior cesarean delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=see_link\">",
"     \"Choosing the route of delivery after cesarean birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uterine perforation is a potential complication of all intrauterine procedures. Injury to surrounding blood vessels or viscera (bladder, bowel) may result. Uterine perforations that are not diagnosed at the time of the procedure can result in hemorrhage or sepsis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that make access to the endometrial cavity difficult or alter the strength of the myometrial wall predispose to uterine perforation (eg, cervical stenosis, uterine malposition, pregnancy, menopause). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On the night before a gynecologic procedure in women with cervical stenosis or for a procedure requiring mechanical dilation, we recommend the use of vaginal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      in premenopausal women (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) and suggest its use in postmenopausal women (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) rather than no preparation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cervical preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In premenopausal women undergoing hysteroscopy, we recommend treatment with vaginal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      on the night before surgery rather than no cervical preparation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We also use misoprostol in postmenopausal women, particularly those with cervical stenosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cervical preparation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=see_link&amp;anchor=H20#H20\">",
"       \"Overview of hysteroscopy\", section on 'Cervical preparation and dilation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women in whom cervical dilation cannot be accomplished using mechanical dilators with gentle pressure, we suggest further attempts be performed under ultrasound guidance (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Difficult cervical dilation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perforation should be suspected with deep penetration of instruments, loss of visualization, excessive bleeding or the identification of fat in the cavity or the curettage specimen. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with suspected or confirmed uterine perforation that occurred during cervical dilation or with a blunt instrument and who are hemodynamically stable, we suggest observation rather than abdominal exploration (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Candidates for observation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abdominal exploration is required for women in whom perforation occurred during use of electrosurgical energy or suction curettage, who are hemodynamically unstable, or in whom there are signs of severe uterine bleeding or vascular or visceral injury are suspected. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Criteria for surgical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For uterine perforation patients who require abdominal exploration and are hemodynamically stable, we suggest laparoscopy rather than laparotomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Use of laparoscopy depends on the availability of a surgeon who can adequately assess the bowel laparoscopically. Immediate laparotomy is generally necessary for patients who are not hemodynamically stable. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Abdominal exploration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uterine perforation may weaken the uterine wall and raises concerns for an increased risk of uterine rupture during subsequent pregnancy. However, this risk is likely minimal in the absence of other risk factors (eg, extensive hysteroscopic surgery, transmural myomectomy, previous cesarean delivery). We do not advise cesarean delivery for women with a uterine perforation who have no other risk factors for uterine rupture. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Effects on future reproduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/1\">",
"      Gentile GP, Siegler AM. Inadvertent intestinal biopsy during laparoscopy and hysteroscopy: a report of two cases. Fertil Steril 1981; 36:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/2\">",
"      Sullivan B, Kenney P, Seibel M. Hysteroscopic resection of fibroid with thermal injury to sigmoid. Obstet Gynecol 1992; 80:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/3\">",
"      Aydeniz B, Gruber IV, Schauf B, et al. A multicenter survey of complications associated with 21,676 operative hysteroscopies. Eur J Obstet Gynecol Reprod Biol 2002; 104:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/4\">",
"      Agostini A, Cravello L, Bretelle F, et al. Risk of uterine perforation during hysteroscopic surgery. J Am Assoc Gynecol Laparosc 2002; 9:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/5\">",
"      Jansen FW, Vredevoogd CB, van Ulzen K, et al. Complications of hysteroscopy: a prospective, multicenter study. Obstet Gynecol 2000; 96:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/6\">",
"      Shveiky D, Rojansky N, Revel A, et al. Complications of hysteroscopic surgery: \"Beyond the learning curve\". J Minim Invasive Gynecol 2007; 14:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/7\">",
"      Hulka JF, Peterson HB, Phillips JM, Surrey MW. Operative hysteroscopy. American Association of Gynecologic Laparoscopists 1991 membership survey. J Reprod Med 1993; 38:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/8\">",
"      Ben-Baruch G, Menczer J, Shalev J, et al. Uterine perforation during curettage: perforation rates and postperforation management. Isr J Med Sci 1980; 16:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/9\">",
"      Grossman D, Blanchard K, Blumenthal P. Complications after second trimester surgical and medical abortion. Reprod Health Matters 2008; 16:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/10\">",
"      Allen RH, Goldberg AB, Board of Society of Family Planning. Cervical dilation before first-trimester surgical abortion (&lt;14 weeks' gestation). SFP Guideline 20071. Contraception 2007; 76:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/11\">",
"      Amarin ZO, Badria LF. A survey of uterine perforation following dilatation and curettage or evacuation of retained products of conception. Arch Gynecol Obstet 2005; 271:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/12\">",
"      Paschopoulos M, Polyzos NP, Lavasidis LG, et al. Safety issues of hysteroscopic surgery. Ann N Y Acad Sci 2006; 1092:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/13\">",
"      Phillips DR, Nathanson HG, Milim SJ, Haselkorn JS. The effect of dilute vasopressin solution on the force needed for cervical dilatation: a randomized controlled trial. Obstet Gynecol 1997; 89:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/14\">",
"      Hobo R, Netsu S, Koyasu Y, Tsutsumi O. Bradycardia and cardiac arrest caused by intramyometrial injection of vasopressin during a laparoscopically assisted myomectomy. Obstet Gynecol 2009; 113:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/15\">",
"      Istre O. Managing bleeding, fluid absorption and uterine perforation at hysteroscopy. Best Pract Res Clin Obstet Gynaecol 2009; 23:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/16\">",
"      Hefler L, Lemach A, Seebacher V, et al. The intraoperative complication rate of nonobstetric dilation and curettage. Obstet Gynecol 2009; 113:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/17\">",
"      Darney PD, Atkinson E, Hirabayashi K. Uterine perforation during second-trimester abortion by cervical dilation and instrumental extraction: a review of 15 cases. Obstet Gynecol 1990; 75:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/18\">",
"      Shulman SG, Bell CL, Hampf FE. Uterine perforation and small bowel incarceration: sonographic and surgical findings. Emerg Radiol 2006; 13:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/19\">",
"      Leibner EC. Delayed presentation of uterine perforation. Ann Emerg Med 1995; 26:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/20\">",
"      Sentilhes L, Sergent F, Berthier A, et al. [Uterine rupture following operative hysteroscopy]. Gynecol Obstet Fertil 2006; 34:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/21\">",
"      Sentilhes L, Sergent F, Roman H, et al. Late complications of operative hysteroscopy: predicting patients at risk of uterine rupture during subsequent pregnancy. Eur J Obstet Gynecol Reprod Biol 2005; 120:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4408/abstract/22\">",
"      Kerimis P, Zolti M, Sinwany G, et al. Uterine rupture after hysteroscopic resection of uterine septum. Fertil Steril 2002; 77:618.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3309 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-7F4984794A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_19_4408=[""].join("\n");
var outline_f4_19_4408=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Uterine perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Associated hemorrhage or visceral injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pre-procedure preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Informed consent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Pre-procedure evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cervical preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Preventive measures during the procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Uterine position",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Difficult cervical dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Safe use of operative instruments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PERIOPERATIVE PRESENTATION OF UTERINE PERFORATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - During the procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Post-procedure clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Candidates for observation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Criteria for surgical management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Abdominal exploration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Completing the original procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Post-procedure monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DELAYED PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      EFFECTS ON FUTURE REPRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3309\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3309|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/7/41074\" title=\"figure 1\">",
"      Ut perf bowel in suction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=related_link\">",
"      An overview of endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18425?source=related_link\">",
"      Blunt genitourinary trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/17/33048?source=related_link\">",
"      Cervical intraepithelial neoplasia: Procedures for cervical conization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5290?source=related_link\">",
"      Choosing the route of delivery after cesarean birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24631?source=related_link\">",
"      Complications of gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23048?source=related_link\">",
"      Congenital cervical anomalies and benign cervical lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35480?source=related_link\">",
"      Dilation and curettage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/131?source=related_link\">",
"      Endometrial sampling procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30408?source=related_link\">",
"      Interventional radiology in management of gynecological disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19898?source=related_link\">",
"      Management of problems related to intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=related_link\">",
"      Overview of conventional gynecologic laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9498?source=related_link\">",
"      Overview of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19498?source=related_link\">",
"      Overview of pregnancy termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=related_link\">",
"      Patient information: Care after gynecologic surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40439?source=related_link\">",
"      Pudendal and paracervical block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42681?source=related_link\">",
"      The gynecologic history and pelvic examination",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_19_4409="Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease";
var content_f4_19_4409=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/19/4409/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4409/contributors\">",
"     Charles D Pusey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4409/contributors\">",
"     Raghu Kalluri, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/19/4409/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4409/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/19/4409/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4409/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/19/4409/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-GBM antibody disease is a disorder in which circulating antibodies are directed against an antigen intrinsic to the glomerular basement membrane (GBM), thereby resulting in acute or rapidly progressive glomerulonephritis that is typically associated with crescent formation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/1\">",
"     1",
"    </a>",
"    ]. Goodpasture's syndrome and Goodpasture's disease are often used synonymously to refer to anti-GBM antibody-mediated disease, which typically presents with the syndrome of glomerulonephritis and pulmonary hemorrhage, but may present with glomerulonephritis alone. However, some use the term Goodpasture's syndrome for the clinical constellation of glomerulonephritis and pulmonary hemorrhage, regardless of the underlying pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/1\">",
"     1",
"    </a>",
"    ]. The term Goodpasture's disease is often reserved for those patients with glomerulonephritis, pulmonary hemorrhage, and anti-GBM antibodies.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical presentation, and diagnosis of anti-GBM disease will be reviewed here. The treatment of this disorder, and other renal conditions associated with pulmonary hemorrhage, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7432?source=see_link\">",
"     \"Treatment of anti-GBM antibody (Goodpasture's) disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H14577579#H14577579\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Acute glomerulonephritis and pulmonary hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of glomerular disease and the approach to the patient with suspected kidney disease are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link\">",
"     \"Differential diagnosis and evaluation of glomerular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is short-lived production of circulating autoantibodies, which are directed against an antigen intrinsic to the glomerular basement membrane (GBM), in response to an unknown inciting stimulus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/2\">",
"     2",
"    </a>",
"    ]. The development of anti-GBM antibodies may precede the onset of clinical signs and symptoms by many months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/3\">",
"     3",
"    </a>",
"    ]. The principal target for the anti-GBM antibodies (which are typically IgG 1 and 3 but sometimes IgA or IgM) is the NC1 domain of the alpha-3 chain of type IV collagen (alpha-3(IV) chain), one of six genetically distinct gene products found in basement membrane collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The specific conformational epitopes are localized to the globular NC1 domain of the alpha-3(IV) (and alpha 5) chain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. These antibodies represent about one percent of the circulating IgG in these patients. Anti-GBM antibodies may also be directed against other alpha chains [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/9\">",
"     9",
"    </a>",
"    ]. Antibodies eluted from the kidneys of patients with Goodpasture's disease were shown to bind most strongly to alpha-3(IV) NC, but the majority also recognized alpha-5(IV) and, to a lesser extent, alpha-4(IV). The kidney bound antibodies recognized the EA and EB epitopes in alpha-3(IV), and the EA epitope in alpha-5(IV). They did not bind native cross-linked alpha-3, 4, 5 hexamers until they were dissociated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cDNA for the alpha-3(IV) chain was cloned and its chromosomal location identified (q35-37 region of the long arm of chromosome 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Cells transfected with the alpha-3(IV) chain cDNA make the protein that binds anti-GBM antibodies, thereby proving that the alpha-3(IV) chain is the target antigen in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenicity of anti-GBM antibodies has been demonstrated by passive transfer experiments in which antibodies obtained from the plasma or eluted from the glomeruli of patients with this disorder produced glomerulonephritis when infused into animals. The ability of these antibodies to bind rapidly and tightly to the GBM may underlie the typically fulminant nature of this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epitope of type IV collagen specifically recognized by anti-GBM antibodies may correlate with the prognosis of the disease. This was illustrated in a review of 77 patients in whom anti-GBM antibodies recognized multiple epitopes of the alpha-3(IV) chain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Titers of antibodies directed against the N-terminus of the NC1 domain correlated with renal survival. In contrast, renal prognosis was unrelated to the titers of antibodies directed against other areas of the NC1 domain.",
"   </p>",
"   <p>",
"    The variable pathogenicity of different anti-GBM antibodies is consistent with a report that antibodies against the alpha-3(IV) chain exist in normal individuals without evidence of renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/18\">",
"     18",
"    </a>",
"    ]. In this report, the anti-GBM titers and avidity were substantially lower and of a different IgG subclass distribution than seen in patients with anti-GBM disease.",
"   </p>",
"   <p>",
"    Experimental models and clinical studies suggest that autoreactive T cells may contribute to the development of anti-GBM antibody disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/7,19-23\">",
"     7,19-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T cells isolated from patients with this disorder, but not from controls, react against the alpha-3 chain of type IV collagen, the same molecule against which the anti-GBM antibodies are directed [",
"      <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/7,24\">",
"       7,24",
"      </a>",
"      ]. Regulatory T cells (CD4+ CD25+) appear to play a role in regulation of the autoimmune response [",
"      <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The administration of an anti-CD8 monoclonal antibody or an anti-CD154 antibody could prevent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treat experimental crescentic glomerulonephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/19,21\">",
"       19,21",
"      </a>",
"      ]. Similarly, regulatory T cells (CD4+ CD25+), which counter the effects of autoreactive T cells, reduce the severity of glomerular lesions in murine anti-GBM glomerulonephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A T cell epitope inducing anti-GBM disease in experimental models has been characterized [",
"      <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. Certain microbial peptides have similarities to this T cell epitope and elicit production of anti-GBM antibody and severe glomerulonephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. Epitope spreading may explain immune responses to other regions of the alpha-3 chain and the alpha-4 chain [",
"      <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations suggest that autoreactive T cells, in addition to enhancing B cell function and antibody production, may have a direct causative role in glomerular and alveolar injury. The presence of potentially autoreactive T cells in normal individuals has been demonstrated by a study showing primary T cell responses to peptides derived from the &plusmn;3(IV) chain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no good data on the population incidence and prevalence. Acute glomerulonephritis due to anti-GBM antibody disease is rare, estimated to occur in fewer than one case per million population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/2\">",
"     2",
"    </a>",
"    ]. In case series published before the 1980s, anti-GBM antibody disease accounted for fewer than 20 percent of cases of rapidly progressive glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In one review of 88 patients who presented with lung hemorrhage and nephritis, 6 had anti-GBM antibodies alone, 7 had both anti-GBM antibodies and positive ANCA titers, and 48 had positive ANCA titers alone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Antineutrophil cytoplasm antibodies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The prevalence among patients presenting for evaluation of potential glomerular disease is lower. Crescentic glomerulonephritis due to anti-GBM antibody disease accounted for fewer than 3 percent of all kidney biopsies done over the course of 10 years in one region of the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/2,31,34\">",
"     2,31,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of anti-GBM disease is made in older children and in adults of all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/2,35\">",
"     2,35",
"    </a>",
"    ]. However, younger patients (&lt;30 years) are more likely to present with the full constellation of Goodpasture's syndrome (eg, with pulmonary hemorrhage), and older patients (&gt;50 years) with isolated glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. There appears to be a slight male predominance in the younger age group, and a female predominance in the older age group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROGNOSIS OF UNTREATED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of untreated acute glomerulonephritis due to anti-GBM antibody disease is extremely poor. In the previously described case series of 67 patients, death or dialysis ensued in over 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/31\">",
"     31",
"    </a>",
"    ]. In another review of 32 patients with Goodpasture's syndrome, 29 progressed to renal failure, most of them in less than six months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/34\">",
"     34",
"    </a>",
"    ]. Among patients with isolated anti-GBM antibody glomerulonephritis, the prognosis was slightly better: 11 progressed to renal failure within six months, seven progressed to renal failure nine months to 22 years later, and three were alive with normal kidney function one to seven years after diagnosis.",
"   </p>",
"   <p>",
"    Prognosis improves following treatment, and recovery is more likely if renal disease is less severe [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/31\">",
"     31",
"    </a>",
"    ]. Since antibody production is short-lived, due to T cell regulatory mechanisms, relapses are rare. These issues, and recurrence after kidney transplantation, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7432?source=see_link\">",
"     \"Treatment of anti-GBM antibody (Goodpasture's) disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22531?source=see_link\">",
"     \"Anti-GBM antibody disease: Recurrence after transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of anti-GBM antibody disease is similar to that of other forms of rapidly progressive glomerulonephritis: relatively acute renal failure with a urinalysis showing proteinuria (which is usually not in the nephrotic range), and a nephritic sediment characterized by dysmorphic red cells, white cells, and red cell and granular casts.",
"   </p>",
"   <p>",
"    Pulmonary involvement, generally consisting of alveolar hemorrhage, affects approximately 30 to 40 percent of patients; such patients are considered to have Goodpasture's syndrome. In rare cases, pulmonary disease predominates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/37\">",
"     37",
"    </a>",
"    ]. Pulmonary manifestations include shortness of breath, cough, sometimes overt hemoptysis, pulmonary infiltrates on chest x-ray, and an increased carbon monoxide diffusing capacity (DLCO) due to the presence of hemoglobin in the alveoli. Iron deficiency anemia, possibly due to prolonged pulmonary bleeding, may be seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"     \"The diffuse alveolar hemorrhage syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with and without alveolar hemorrhage appear to have similar auto-antibodies against the alpha-3(IV) chain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/4\">",
"     4",
"    </a>",
"    ], and also to the alpha-5 chain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/10\">",
"     10",
"    </a>",
"    ]. The variable presence of pulmonary disease appears to reflect a general lack of access of the circulating anti-GBM antibodies to the alveolar basement membrane, or to the cryptic nature of the antigen Thus, patients with pulmonary involvement often have underlying pulmonary injury due to smoking or, less frequently, infection, cocaine inhalation, or hydrocarbon exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic complaints and signs, such as malaise, weight loss, fever, or arthralgia, are typically absent. The presence of such signs suggests that the patient has a concurrent vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Antineutrophil cytoplasm antibodies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The general limitation of injury to the glomeruli and alveoli appears to reflect the tissue distribution of the alpha-3(IV) chain. In comparison to the more widespread distribution of the alpha-1 and alpha-2 chains of type IV collagen, expression of the alpha-3 chain is highest in the glomerular and alveolar basement membranes, lower in the renal tubular basement membranes, detectable in the choroid plexus, cochlea and retina, and virtually absent in many other tissues, such as the small intestine and placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A relatively mild degree of renal involvement may be more common than previously appreciated in patients with anti-GBM antibody disease. A retrospective review from one center in Australia found that 5 of 14 patients (36 percent) with this disorder had hematuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria, but a normal creatinine clearance or serum concentration of creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/43\">",
"     43",
"    </a>",
"    ]. Other series have found that 15 to 35 percent of patients have \"normal\" renal function, which is variably defined as a normal urinary sediment or no evidence of a fall in glomerular filtration rate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/43\">",
"     43",
"    </a>",
"    ]. However, such cases clearly have the potential to progress rapidly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Associated factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-GBM antibody disease is most often idiopathic, although it can occasionally follow pulmonary infections or be associated with pulmonary injury. The association with infections may lead to clustering of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One hypothesis to explain the association of pulmonary involvement with smoking or pulmonary infections is that ensuing damage reveals an epitope that incites an immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/1\">",
"     1",
"    </a>",
"    ]. Another possibility is that damage to alveolar capillaries that occurs in these settings allows access of existing circulating anti-GBM antibodies to antigen in the alveolar basement membrane. Isolated cases of anti-GBM disease with pulmonary hemorrhage, but without renal involvement, have been reported. Damage to the GBM has been proposed as an explanation for the association of anti-GBM renal disease with urinary tract obstruction and lithotripsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/1,44\">",
"     1,44",
"    </a>",
"    ]. Anti-GBM disease is also commonly associated with primary systemic vasculitis (see below) and less commonly occurs on a background of membranous glomerulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One interesting setting in which this disorder can occur is 5 to 10 percent of renal transplants in patients with underlying hereditary nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/46\">",
"     46",
"    </a>",
"    ]. These patients most commonly have an abnormality in the alpha-5 chain of type IV collagen, although alpha-3 and alpha-4 chain abnormalities may occur. This leads to defective organization of the alpha-5, -4 and -3 collagen chains in the basement membrane and altered Goodpasture antigen in the alpha-3 chain, so it is not recognized by anti-GBM antibodies. In comparison, the Goodpasture antigen is normal in the donor kidney, potentially initiating an immune response against this previously \"unseen\" antigen in the transplanted kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/46\">",
"     46",
"    </a>",
"    ]. The alloantibody produced in X-linked Alport post-transplantation nephritis, however, recognizes a different epitope than the autoantibody in Goodpasture's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that genetic factors affect the susceptibility to anti-GBM antibody disease. Patients with HLA-DR15 and DR4 appear to be at increased risk, while those with DR1 and DR7 are at lesser risk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/47\">",
"     47",
"    </a>",
"    ]. The association with DR15 has been confirmed in Chinese [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/48\">",
"     48",
"    </a>",
"    ] and Japanese patient [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/49\">",
"     49",
"    </a>",
"    ]. More specific molecular analysis of DR&szlig; chains has found that a particular six amino acid motif common to DRw15 and DR4 may confer disease susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/50\">",
"     50",
"    </a>",
"    ]. This motif is not seen in DR1 and is uncommon in blacks, who also have a lower incidence of anti-GBM antibody disease.",
"   </p>",
"   <p>",
"    The importance of genetic factors in determining the development of anti-GBM antibody disease is supported by findings in rodent models. In mice immunized with alpha-3(IV) NC1, the emergence of crescentic glomerulonephritis and lung hemorrhage was restricted to mice with MHC haplotypes H-2s, b, or d [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/51\">",
"     51",
"    </a>",
"    ]. The nephritogenic response in H-2s maps more specifically to the",
"    <span class=\"nowrap\">",
"     Ab/Aa",
"    </span>",
"    region. Organ inflammation was also associated with the emergence of an",
"    <span class=\"nowrap\">",
"     IL-12/Th1-like",
"    </span>",
"    T cell phenotype, a finding consistent with a role for T cells as mentioned above. In rats with experimental anti-GBM glomerulonephritis, susceptibility was determined by copy number variation in the Fcgr3 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/52\">",
"     52",
"    </a>",
"    ]., and by expression of the AP-1 transcription factor JunD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/53\">",
"     53",
"    </a>",
"    ]. Studies in congenic rats showed that both of these genetic loci have effects on susceptibility by modulating macrophage activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of anti-GBM antibody disease should be suspected in any patient with acute glomerulonephritis, particularly if accompanied by rapid progression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary (alveolar) hemorrhage. Pulmonary hemorrhage can also be seen with other acute nephritides due to pulmonary edema, or to lung involvement in ANCA positive and other forms of systemic vasculitis, and lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/38\">",
"     38",
"    </a>",
"    ]. In one report of 45 such patients, eight had anti-GBM antibody disease, while 25 had a systemic vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H14577579#H14577579\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Acute glomerulonephritis and pulmonary hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of anti-GBM antibody disease requires demonstration of anti-GBM antibodies either in the serum or the kidney. Renal biopsy should be performed, unless there is a contraindication, because the accuracy of serologic assays is variable. In addition, renal biopsy provides important information regarding the activity and chronicity of renal involvement that may help guide therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Light microscopy usually shows crescentic glomerulonephritis (although milder cases do occur), whereas immunofluorescence microscopy demonstrates the virtually pathognomonic finding of linear deposition of IgG along the glomerular capillaries and occasionally the distal tubules (",
"    <a class=\"graphic graphic_picture graphicRef68861 graphicRef76472 graphicRef63060 graphicRef57096 graphicRef78020 \" href=\"UTD.htm?43/36/44618\">",
"     picture 1A-E",
"    </a>",
"    ). In rare cases, the antibody may be IgA or IgM [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some cases, the tubular staining reflects distinct circulating anti-tubular basement membrane (TBM) antibodies. The observation that the associated tubulointerstitial disease (interstitial infiltrate and fibrosis, tubular atrophy) is more severe in patients with anti-TBM antibodies is consistent with these antibodies being pathogenetically important [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/56\">",
"     56",
"    </a>",
"    ]. However, alpha-3(IV) NC1 is present in a proportion of tubules (distal), so tubular deposits may reflect increased access of anti-GBM antibody to the TBM.",
"   </p>",
"   <p>",
"    There are two other disorders in which linear IgG staining can be seen in the glomeruli: diabetic nephropathy and fibrillary glomerulonephritis. In the former and perhaps in the latter, the IgG is nonspecifically absorbed onto the highly permeable glomerular capillary wall and onto the fibrils, respectively. Staining is rarely as strong as with anti-GBM disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33064?source=see_link\">",
"     \"Glomerular diseases due to nonamyloid fibrillar deposits\"",
"    </a>",
"    .) In diabetic nephropathy, there is also linear deposition of albumin and other plasma proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetic nephropathy and fibrillary glomerulonephritis can be easily distinguished from anti-GBM disease on both clinical and histopathologic grounds. Circulating anti-GBM antibodies are absent in both disorders, and crescents are not seen in diabetic nephropathy. The history of diabetes, the finding of diabetic glomerulosclerosis on light microscopy, and, in fibrillary glomerulonephritis, the presence of the characteristic fibrils on electron microscopy are also helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis can usually be established rapidly (particularly when biopsy cannot be performed or will be delayed), either by indirect immunofluorescence or by serum assay for anti-GBM antibodies using a direct enzyme-linked immunoassay (ELISA) with purified or semi-purified antigens. Neither method is completely reliable; thus, a renal biopsy to confirm the diagnosis is recommended unless contraindicated.",
"   </p>",
"   <p>",
"    Indirect immunofluorescence is rarely performed and requires an experienced renal pathologist. This test involves incubation of the patient's serum with normal renal tissue. Fluorescein-labeled anti-human IgG is then added to see if IgG deposition has occurred, and the results are compared to those obtained with normal serum. The test has a high false negative rate, possibly as high as 40 percent. However, if performed appropriately and in the proper clinical setting (eg, severe acute glomerulonephritis), a positive test is probably diagnostic, although rigorous studies have not been performed.",
"   </p>",
"   <p>",
"    A more common approach is the detection of anti-GBM antibodies in serum using a direct enzyme-linked immunoassay (ELISA); the specificity of the antibody can be confirmed by Western blot [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/58\">",
"     58",
"    </a>",
"    ]. High antibody titers are usually found in those with rapidly progressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The sensitivity varies depending upon the commercial kit used, ranging from 63 to nearly 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. False negative results may occur in those with low antibody titers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/59\">",
"     59",
"    </a>",
"    ] and in some patients with Alport syndrome who develop post-transplant anti-GBM disease, with antibodies directed against the alpha-5(IV) chain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    False positive results occasionally occur with commercial ELISA assays that do not use purified Goodpasture antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/58,60,63\">",
"     58,60,63",
"    </a>",
"    ]. ELISA assays for the detection of anti-GBM antibodies that use native or recombinant human alpha-3(IV) antigen substrates are much more sensitive and specific, with reported sensitivity of 95 to 100 percent and specificity of 91 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative is Western blot screening for antibody against the human Goodpasture antigen (alpha-3(IV) NC1) and, as controls, other human alpha chain proteins. Eliminating false positive results is particularly important if renal biopsy confirmation is not available. The patient's a priori probability of having the disease based on clinical grounds must be strongly considered when interpreting the results of serologic tests.",
"   </p>",
"   <p>",
"    One case report provides an example in which commercial tests inaccurately suggested that a patient had anti-GBM antibodies, which was clarified using recombinant human alpha-3(IV) NC1 proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/63\">",
"     63",
"    </a>",
"    ]. A patient with slowly progressive dyspnea, hematuria, and proteinuria had positive circulating anti-GBM antibodies as detected by standard testing and, on renal biopsy, trace linear IgG deposits along the GBM. Repeat testing using standard commercial assays and recombinant human alpha-3(IV) NC1 demonstrated that the patient had antibodies against alpha-2(IV) NC1 and not to the Goodpasture antigen alpha-3(IV) NC1. When viewed in combination with the atypical clinical and histologic findings, the positive commercial tests were probably detecting nonspecific cross-reactivity to alpha-3(IV) NC1, and the alpha-2(IV) NC1 antibodies were nonpathogenic bystanders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antineutrophil cytoplasm antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute glomerulonephritis with or without pulmonary hemorrhage also may have granulomatosis with polyangiitis (Wegener's), or microscopic polyangiitis. Thus, the serum should be tested for antineutrophil cytoplasm antibodies (ANCA), as well as anti-GBM antibodies. Anti-GBM disease and systemic vasculitis not only have similar clinical manifestations, but between 10 and 38 percent of patients with anti-GBM antibody disease also test positively for ANCA (almost always anti-myeloperoxidase, or MPO-ANCA) at the time of diagnosis and may have signs of a systemic vasculitis or a marked systemic inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low levels of ANCA may be detectable years before the production of anti-GBM antibodies and the onset of clinical symptoms. This was shown by an analysis of stored serum samples that had been obtained at the time of enlistment and every other year thereafter from 30 US military personnel who subsequently developed anti-GBM disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients who were diagnosed with anti-GBM disease and healthy controls were identified from the military database and serum samples obtained from the Department of Defense Stored Serum Repository. Compared with matching controls, a greater number of patients with anti-GBM disease had anti-proteinase 3 (PR3-ANCA) and anti-myeloperoxidase (MPO-ANCA) levels detected in multiple serum samples that had been obtained in the years preceding the onset of disease (82 versus 14 percent in controls for PR3-ANCA, and 73 versus 27 percent in controls for MPO-ANCA). In all cases, ANCA were detected in earlier samples than anti-GBM antibodies, which were detected months, but not years, prior to the onset of clinical symptoms. These data implicate ANCA in disease pathogenesis though the mechanism remains unknown.",
"   </p>",
"   <p>",
"    Even if the patient was negative for ANCA on initial testing, ANCA serology should be repeated if there are signs of recurrent disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The anti-GBM antibodies in patients who also have ANCA (double-positive) have the same antigen specificity as those in patients with anti-GBM antibody disease alone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/66\">",
"     66",
"    </a>",
"    ]. However, a single center Chinese study found that double-positive patients may have lower levels but a broader spectrum of anti-GBM antibodies compared with those with anti-GBM antibodies alone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/67\">",
"     67",
"    </a>",
"    ]. In addition, ANCA positive patients may develop a relapse of systemic vasculitis.",
"   </p>",
"   <p>",
"    The detection of ANCA is clinically relevant, as these patients may be more likely to have treatable disease than those who have only anti-GBM antibodies. However, larger series suggest that the initial outcome is similar to those with anti-GBM disease alone l [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4409/abstract/65,68\">",
"     65,68",
"    </a>",
"    ]. Longer term management should be tailored to the vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7432?source=see_link\">",
"     \"Treatment of anti-GBM antibody (Goodpasture's) disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-GBM antibody disease is a disorder in which circulating antibodies are directed mainly against the NC1 domain of the alpha-3 chain of type IV collagen, which is highly expressed in the GBM and alveoli. Antibodies against the alpha-5 chain are also commonly present.",
"   </p>",
"   <p>",
"    Patients with anti-GBM antibody disease usually present with rapidly progressive glomerulonephritis: acute renal failure, nephritic urine sediment, and non-nephrotic proteinuria. Pulmonary involvement (alveolar hemorrhage) is present in 50 to 60 percent of patients. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Systemic complaints and signs are typically absent, and, if present, suggest concurrent vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"     \"The diffuse alveolar hemorrhage syndromes\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Antineutrophil cytoplasm antibodies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnosis requires demonstration of anti-GBM antibodies; thus, we recommend the following for all patients suspected to have anti-GBM antibody disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kidney biopsy, unless contraindicated, since demonstration of linear deposits of IgG (which represent binding of anti-GBM antibodies to the GBM) in the specimen is diagnostic, and activity and chronicity of renal involvement may help guide therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Renal biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serologic testing for anti-GBM antibodies. This may be particularly useful if biopsy cannot be done or will be delayed, although none of the available tests are completely reliable. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Serologic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest serologic testing using direct enzyme-linked immunoassay (ELISA) kits that utilize native (eg, bovine) or recombinant human alpha-3(IV) NC1.",
"     </li>",
"     <li>",
"      If available, we suggest confirmatory Western blot testing in patients with a positive ELISA, especially if a kidney biopsy will not be performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testing for antineutrophil cytoplasm antibodies (ANCA), since up to 40 percent of patients with anti-GBM antibody disease also test positive for ANCA at the time of diagnosis and may have a systemic vasculitis, which may alter treatment decisions and prognosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antineutrophil cytoplasm antibodies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/1\">",
"      Pusey CD. Anti-glomerular basement membrane disease. Kidney Int 2003; 64:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/2\">",
"      Bolton WK. Goodpasture's syndrome. Kidney Int 1996; 50:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/3\">",
"      Olson SW, Arbogast CB, Baker TP, et al. Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol 2011; 22:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/4\">",
"      Kalluri R, Wilson CB, Weber M, et al. Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. J Am Soc Nephrol 1995; 6:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/5\">",
"      Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/6\">",
"      Kalluri R, Sun MJ, Hudson BG, Neilson EG. The Goodpasture autoantigen. Structural delineation of two immunologically privileged epitopes on alpha3(IV) chain of type IV collagen. J Biol Chem 1996; 271:9062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/7\">",
"      Merkel F, Kalluri R, Marx M, et al. Autoreactive T-cells in Goodpasture's syndrome recognize the N-terminal NC1 domain on alpha 3 type IV collagen. Kidney Int 1996; 49:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/8\">",
"      Leinonen A, Netzer KO, Boutaud A, et al. Goodpasture antigen: expression of the full-length alpha3(IV) chain of collagen IV and localization of epitopes exclusively to the noncollagenous domain. Kidney Int 1999; 55:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/9\">",
"      Zhao J, Cui Z, Yang R, et al. Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity. Kidney Int 2009; 76:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/10\">",
"      Pedchenko V, Bondar O, Fogo AB, et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 2010; 363:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/11\">",
"      Morrison KE, Mariyama M, Yang-Feng TL, Reeders ST. Sequence and localization of a partial cDNA encoding the human alpha 3 chain of type IV collagen. Am J Hum Genet 1991; 49:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/12\">",
"      Turner N, Mason PJ, Brown R, et al. Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen. J Clin Invest 1992; 89:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/13\">",
"      Neilson EG, Kalluri R, Sun MJ, et al. Specificity of Goodpasture autoantibodies for the recombinant noncollagenous domains of human type IV collagen. J Biol Chem 1993; 268:8402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/14\">",
"      Turner N, Forstov&aacute; J, Rees A, et al. Production and characterization of recombinant Goodpasture antigen in insect cells. J Biol Chem 1994; 269:17141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/15\">",
"      Rutgers A, Meyers KE, Canziani G, et al. High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients to alpha3(IV)NC1 collagen. Kidney Int 2000; 58:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/16\">",
"      Hellmark T, Segelmark M, Unger C, et al. Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease. Kidney Int 1999; 55:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/17\">",
"      Kalluri R. Goodpasture syndrome. Kidney Int 1999; 55:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/18\">",
"      Cui Z, Wang HY, Zhao MH. Natural autoantibodies against glomerular basement membrane exist in normal human sera. Kidney Int 2006; 69:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/19\">",
"      Reynolds J, Norgan VA, Bhambra U, et al. Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis. J Am Soc Nephrol 2002; 13:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/20\">",
"      Salama AD, Chaudhry AN, Holthaus KA, et al. Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. Kidney Int 2003; 64:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/21\">",
"      Reynolds J, Khan SB, Allen AR, et al. Blockade of the CD154-CD40 costimulatory pathway prevents the development of experimental autoimmune glomerulonephritis. Kidney Int 2004; 66:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/22\">",
"      Dean EG, Wilson GR, Li M, et al. Experimental autoimmune Goodpasture's disease: a pathogenetic role for both effector cells and antibody in injury. Kidney Int 2005; 67:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/23\">",
"      Wolf D, Hochegger K, Wolf AM, et al. CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol 2005; 16:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/24\">",
"      Salama AD, Chaudhry AN, Ryan JJ, et al. In Goodpasture's disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3(IV)NC1. J Am Soc Nephrol 2001; 12:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/25\">",
"      Wu J, Borillo J, Glass WF, et al. T-cell epitope of alpha3 chain of type IV collagen induces severe glomerulonephritis. Kidney Int 2003; 64:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/26\">",
"      Robertson J, Wu J, Arends J, et al. Characterization of the T-cell epitope that causes anti-GBM glomerulonephritis. Kidney Int 2005; 68:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/27\">",
"      Arends J, Wu J, Borillo J, et al. T cell epitope mimicry in antiglomerular basement membrane disease. J Immunol 2006; 176:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/28\">",
"      Wu J, Arends J, Borillo J, et al. A self T cell epitope induces autoantibody response: mechanism for production of antibodies to diverse glomerular basement membrane antigens. J Immunol 2004; 172:4567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/29\">",
"      Chen L, Hellmark T, Pedchenko V, et al. A nephritogenic peptide induces intermolecular epitope spreading on collagen IV in experimental autoimmune glomerulonephritis. J Am Soc Nephrol 2006; 17:3076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/30\">",
"      Zou J, Hannier S, Cairns LS, et al. Healthy individuals have Goodpasture autoantigen-reactive T cells. J Am Soc Nephrol 2008; 19:396.",
"     </a>",
"    </li>",
"    <li>",
"     Bolton WK. The role of high dose steroids in nephritic syndromes: The case for aggressive use. In: Controversies in Nephrology and Hypertension, Narins RJ (Ed), Churchill Livingstone, New York City 1984. p.421.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/32\">",
"      McLeish KR, Yum MN, Luft FC. Rapidly progressive glomerulonephritis in adults: clinical and histologic correlations. Clin Nephrol 1978; 10:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/33\">",
"      Niles JL, B&ouml;ttinger EP, Saurina GR, et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med 1996; 156:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/34\">",
"      Wilson CB, Dixon FJ. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 1973; 3:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/35\">",
"      Savage CO, Pusey CD, Bowman C, et al. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed) 1986; 292:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/36\">",
"      Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 2001; 134:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/37\">",
"      Lazor R, Bigay-Gam&eacute; L, Cottin V, et al. Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases. Medicine (Baltimore) 2007; 86:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/38\">",
"      Boyce NW, Holdsworth SR. Pulmonary manifestations of the clinical syndrome of acute glomerulonephritis and lung hemorrhage. Am J Kidney Dis 1986; 8:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/39\">",
"      Donaghy M, Rees AJ. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet 1983; 2:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/40\">",
"      Garc&iacute;a-Rostan y P&eacute;rez GM, Garc&iacute;a Bragado F, Puras Gil AM. Pulmonary hemorrhage and antiglomerular basement membrane antibody-mediated glomerulonephritis after exposure to smoked cocaine (crack): a case report and review of the literature. Pathol Int 1997; 47:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/41\">",
"      Kluth DC, Rees AJ. Anti-glomerular basement membrane disease. J Am Soc Nephrol 1999; 10:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/42\">",
"      Derry CJ, Pusey CD. Tissue-specific distribution of the Goodpasture antigen demonstrated by 2-D electrophoresis and western blotting. Nephrol Dial Transplant 1994; 9:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/43\">",
"      Ang C, Savige J, Dawborn J, et al. Anti-glomerular basement membrane (GBM)-antibody-mediated disease with normal renal function. Nephrol Dial Transplant 1998; 13:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/44\">",
"      Umekawa T, Kohri K, Yoshioka K, et al. Production of anti-glomerular basement membrane antibody after extracorporeal shock wave lithotripsy. Urol Int 1994; 52:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/45\">",
"      Sano T, Kamata K, Shigematsu H, Kobayashi Y. A case of anti-glomerular basement membrane glomerulonephritis superimposed on membranous nephropathy. Nephrol Dial Transplant 2000; 15:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/46\">",
"      Kalluri R, Weber M, Netzer KO, et al. COL4A5 gene deletion and production of post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome. Kidney Int 1994; 45:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/47\">",
"      Phelps RG, Rees AJ. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. Kidney Int 1999; 56:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/48\">",
"      Yang R, Cui Z, Zhao J, Zhao MH. The role of HLA-DRB1 alleles on susceptibility of Chinese patients with anti-GBM disease. Clin Immunol 2009; 133:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/49\">",
"      Kitagawa W, Imai H, Komatsuda A, et al. The HLA-DRB1*1501 allele is prevalent among Japanese patients with anti-glomerular basement membrane antibody-mediated disease. Nephrol Dial Transplant 2008; 23:3126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/50\">",
"      Fisher M, Pusey CD, Vaughan RW, Rees AJ. Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes. Kidney Int 1997; 51:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/51\">",
"      Kalluri R, Danoff TM, Okada H, Neilson EG. Susceptibility to anti-glomerular basement membrane disease and Goodpasture syndrome is linked to MHC class II genes and the emergence of T cell-mediated immunity in mice. J Clin Invest 1997; 100:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/52\">",
"      Aitman TJ, Dong R, Vyse TJ, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006; 439:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/53\">",
"      Behmoaras J, Bhangal G, Smith J, et al. Jund is a determinant of macrophage activation and is associated with glomerulonephritis susceptibility. Nat Genet 2008; 40:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/54\">",
"      Behmoaras J, Smith J, D'Souza Z, et al. Genetic loci modulate macrophage activity and glomerular damage in experimental glomerulonephritis. J Am Soc Nephrol 2010; 21:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/55\">",
"      Borza DB, Chedid MF, Colon S, et al. Recurrent Goodpasture's disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1/alpha2 chains of type IV collagen. Am J Kidney Dis 2005; 45:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/56\">",
"      Andres G, Brentjens J, Kohli R, et al. Histology of human tubulo-interstitial nephritis associated with antibodies to renal basement membranes. Kidney Int 1978; 13:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/57\">",
"      Burns AP, Fisher M, Li P, et al. Molecular analysis of HLA class II genes in Goodpasture's disease. QJM 1995; 88:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/58\">",
"      Kalluri R, Petrides S, Wilson CB, et al. Anti-alpha1(IV) collagen autoantibodies associated with lung adenocarcinoma presenting as the Goodpasture syndrome. Ann Intern Med 1996; 124:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/59\">",
"      Salama AD, Dougan T, Levy JB, et al. Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. Am J Kidney Dis 2002; 39:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/60\">",
"      Litwin CM, Mouritsen CL, Wilfahrt PA, et al. Anti-glomerular basement membrane disease: role of enzyme-linked immunosorbent assays in diagnosis. Biochem Mol Med 1996; 59:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/61\">",
"      Sinico RA, Radice A, Corace C, et al. Anti-glomerular basement membrane antibodies in the diagnosis of Goodpasture syndrome: a comparison of different assays. Nephrol Dial Transplant 2006; 21:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/62\">",
"      Browne G, Brown PA, Tomson CR, et al. Retransplantation in Alport post-transplant anti-GBM disease. Kidney Int 2004; 65:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/63\">",
"      Charytan D, MacDonald B, Sugimoto H, et al. An unusual case of pulmonary-renal syndrome associated with defects in type IV collagen composition and anti-glomerular basement membrane autoantibodies. Am J Kidney Dis 2005; 45:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/64\">",
"      Kalluri R, Meyers K, Mogyorosi A, et al. Goodpasture syndrome involving overlap with Wegener's granulomatosis and anti-glomerular basement membrane disease. J Am Soc Nephrol 1997; 8:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/65\">",
"      Levy JB, Hammad T, Coulthart A, et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004; 66:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/66\">",
"      Hellmark T, Niles JL, Collins AB, et al. Comparison of anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol 1997; 8:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/67\">",
"      Yang R, Hellmark T, Zhao J, et al. Antigen and epitope specificity of anti-glomerular basement membrane antibodies in patients with goodpasture disease with or without anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 2007; 18:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4409/abstract/68\">",
"      Rutgers A, Slot M, van Paassen P, et al. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis 2005; 46:253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3108 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-DE283444F4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_19_4409=[""].join("\n");
var outline_f4_19_4409=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROGNOSIS OF UNTREATED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Associated factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antineutrophil cytoplasm antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3108\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3108|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/27/21945\" title=\"picture 1A\">",
"      RPGN Light High",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/55/22393\" title=\"picture 1B\">",
"      RPGN Light High II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/33/1552\" title=\"picture 1C\">",
"      Anti GBM disease IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/11/17599\" title=\"picture 1D\">",
"      RPGN IF Fibrin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/56/25480\" title=\"picture 1E\">",
"      RPGN EM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22531?source=related_link\">",
"      Anti-GBM antibody disease: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33064?source=related_link\">",
"      Glomerular diseases due to nonamyloid fibrillar deposits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7432?source=related_link\">",
"      Treatment of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_19_4410="Environmental electrical injuries";
var content_f4_19_4410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Environmental electrical injuries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/19/4410/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4410/contributors\">",
"     Duane S Pinto, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4410/contributors\">",
"     Peter F Clardy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/19/4410/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4410/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4410/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/19/4410/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/19/4410/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/19/4410/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical injuries are relatively common, nearly always accidental, and generally preventable. The direct effect of electrical current, conversion of electrical to thermal energy, and blunt mechanical trauma can result in tissue destruction and organ dysfunction. Appropriate therapy includes management of trauma and a detailed physical assessment. Multiple surgical interventions, including fasciotomy and skin grafting, and prolonged supportive care may be required.",
"   </p>",
"   <p>",
"    Electrical injuries will be reviewed here. The evaluation and management of burns, general aspects of trauma management, and injuries related to electrosurgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=see_link\">",
"     \"Overview of electrosurgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14469301\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical burns and lightning injuries are estimated to result in more than 3000 admissions to specialized burn units each year in the United States, and account for 3 to 4 percent of all burn-related injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Up to 40 percent of serious electrical injuries are fatal, resulting in an estimated 1000 deaths per year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a bimodal distribution of environmental electrical injuries with respect to age. Work-related injuries in adults, and accidents in children, account for most electrical injuries. Incidence is increased among children younger than six years, often because of contact with electric cords or outlets [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]; older children generally suffer high-voltage injuries from power lines while climbing trees or utility poles [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of electrical injuries decreases through the teenage years and increases again as adults enter the workplace. Together, construction and electrical workers account for about two-thirds of all electrical injuries. Electrical injuries are the second leading cause of occupation-related deaths in the United States. There is an approximately 2:1 male to female ratio in childhood; among adults, more than 90 percent of victims are men [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/1,5,6,10,11\">",
"     1,5,6,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Lightning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lightning injuries, a small subset of electrical injuries, are responsible for an average of 300 injuries and 100 deaths per year in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/3,12-14\">",
"     3,12-14",
"    </a>",
"    ]. It is likely that lightning-related fatalities and hospitalizations are underestimated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/15\">",
"     15",
"    </a>",
"    ]. Approximately 30 percent of those struck by lightning die and up to 74 percent of survivors may have permanent disabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/4,12,16\">",
"     4,12,16",
"    </a>",
"    ]. Two-thirds of lightning-associated deaths occur within one hour of injury and are generally due to a fatal arrhythmia or respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is significant temporal variation in lightning-related fatalities; over 90 percent occur during the spring and summer, and roughly 70 percent occur during the afternoon and early evening [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. More than one-half of all lightning-related fatalities occur while people are engaged in outdoor recreational activities; another 25 percent happen when working outdoors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/17,19\">",
"     17,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The victims of most fatal lightning injuries are young men. According to data from the Centers for Disease Control (CDC), between 1980 and 1996, 85 percent of 1318 people reported killed by lightning were male, and 68 percent were aged 15 to 44 years. The greatest number of deaths attributable to lightning occurred in Florida and Texas, but New Mexico, Arizona, Arkansas, and Mississippi had the highest incidence (9 to 10 per 10,000,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ELECTRICAL WEAPONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical weapons, including the stun gun and the Taser&reg;, have been developed for use by law enforcement and security personnel to provide less lethal alternatives to conventional weapons, including handguns [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/20\">",
"     20",
"    </a>",
"    ]. These devices deliver bursts of high-voltage, low-amperage direct current, either through a handheld device (stun gun) or through a hook and wire system fired using compressed gas (Taser&reg;) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/21\">",
"     21",
"    </a>",
"    ]. Electrical weapons are widely available and have been used for criminal purposes and torture [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of the clinical studies of electrical weapons found no evidence that they cause &ldquo;dangerous laboratory abnormalities, physiologic changes, or immediate or delayed cardiac ischemia or arrhythmias&rdquo; when exposure lasts 15 seconds or less [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/22\">",
"     22",
"    </a>",
"    ]. Subsequent reviews and studies have reported similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. A study of electrical weapons use against minors (n=100; median age 16 years) reported no significant injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/25\">",
"     25",
"    </a>",
"    ]. We agree with the authors of two systematic reviews, who conclude that prolonged observation and diagnostic testing are",
"    <strong>",
"     not",
"    </strong>",
"    necessary in patients who are otherwise asymptomatic and alert following such an exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in rare instances, fatal arrhythmias have been reported in patients shot by electrical weapons [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. One report noted fatal cardiac arrest in 3 of 218 people who received medical attention within 5 to 25 minutes following Taser&reg; injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/26\">",
"     26",
"    </a>",
"    ]. This study likely overestimates the risk of cardiac arrest, since only those individuals who required medical attention were included in the analysis. Concurrent intoxication with cocaine, methamphetamine, phencyclidine (PCP) or other stimulants is common among those subdued by law enforcement with electrical weapons and may increase the risk of cardiac arrhythmia, as may preexisting cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/21,23,26,28\">",
"     21,23,26,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=see_link\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=see_link\">",
"     \"Methamphetamine intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=see_link\">",
"     \"Phencyclidine (PCP) intoxication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    People can be injured if they fall after being &ldquo;stunned,&rdquo; and such patients should be carefully examined, including diagnostic studies as indicated. Significant injuries reported in association with electrical weapons are rare, but may include cutaneous burns, lacerations, rhabdomyolysis, testicular torsion, ocular injury, and miscarriage [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/21,29\">",
"     21,29",
"    </a>",
"    ]. Evaluation of the trauma patient is discussed separately; the management of cutaneous injuries is supportive and is similar to the treatment of other types of electrical injuries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHYSICS OF ELECTRICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electricity is defined as the flow of electrons between points of high concentration to points of lower concentration (or potential). The electrical current is the volume (or actual number) of electrons that flow between these points per second, measured in amperes. In an alternating current (AC), the direction of flow of electrons changes on a cyclical basis. Standard household current is AC alternating at 60 cycles per second. With direct current (DC), the direction of flow remains constant. DC current is found in batteries, railway tracks, automobile electrical systems, and lightning.",
"   </p>",
"   <p>",
"    The force that drives the electrons across the potential difference is the voltage (V). Resistance (R) describes the hindrance to flow. The interrelationship among current (I), voltage, and resistance is described by Ohm's law:",
"   </p>",
"   <p>",
"    I &nbsp;= &nbsp;",
"    <span class=\"nowrap\">",
"     V/R",
"    </span>",
"   </p>",
"   <p>",
"    Stated another way, current is directly proportional to the voltage and inversely proportional to resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries due to electricity occur by three mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Direct effect of electrical current on body tissues",
"     </li>",
"     <li>",
"      Conversion of electrical energy to thermal energy, resulting in deep and superficial burns",
"     </li>",
"     <li>",
"      Blunt mechanical injury from lightning strike, muscle contraction, or as a complication of a fall after electrocution",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary determinant of injury is the amount of current flowing through the body. Clinically, contact with a 120 V circuit carrying a 1 milliampere (mA) current is imperceptible to most persons, 3 mA leads to mild tingling, and 10 to 12 mA leads to pain. One hundred mA directed across the heart can cause ventricular fibrillation (",
"    <a class=\"graphic graphic_table graphicRef75610 \" href=\"UTD.htm?31/35/32315\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In addition, the voltage, resistance, type of current (AC or DC), the current pathway, and duration of contact all influence the extent of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tissue damage inflicted by most electrical currents can be primarily attributed to the thermal energy (or heat) generated by the current, as predicted by Joule's law:",
"   </p>",
"   <p>",
"    &nbsp;Heat = current (I) x voltage (V) x time of contact (t)",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;= I x V x t",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;= I x (I x R) x t (from Ohm's Law)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;= I",
"    <sup>",
"     2",
"    </sup>",
"    x R x t",
"   </p>",
"   <p>",
"    Resistance is a function of the area of contact, pressure applied, and the presence of moisture. Tissues with higher resistance have a tendency to heat up and coagulate, rather than transmit current. Skin, bone, and fat have high resistances, while nerves and blood vessels have lower resistances.",
"   </p>",
"   <p>",
"    Of all organ systems, the skin has the greatest effect on the severity of an electrical injury. Dry skin has a resistance of approximately 100,000 ohms; however, this drops to less than 2500 ohms when the skin is dampened [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, in some cases, a lower voltage applied to tissue with low resistance can generate more current and be more damaging than higher voltage applied to tissue with high resistance.",
"   </p>",
"   <p>",
"    DC current tends to cause a single muscle spasm that throws the victim from the source. This results in a shorter duration of exposure, but a higher likelihood of associated trauma. In contrast, AC repetitively stimulates muscle contraction. Often, the site of exposure is at the hand, and because the flexors of the arm are stronger than the extensors, the victim may actually grasp the source, prolonging the duration of contact and perpetuating tissue injury.",
"   </p>",
"   <p>",
"    The amount of AC needed to cause injury varies in proportion to its frequency, expressed in cycles per second or hertz (Hz). Skeletal muscle can become tetanic with frequencies between 15 and 150 Hz, and although a 20 mA current may not be perceptible at 10 Hz, the same current may cause respiratory paralysis or ventricular fibrillation at lower frequencies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/9,34,35\">",
"     9,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As voltage is often the only variable known with certainty, electrical injuries are generally classified as being high voltage (&gt;1000 V) or low voltage (&lt;1000 V) (",
"    <a class=\"graphic graphic_table graphicRef77842 \" href=\"UTD.htm?25/11/25788\">",
"     table 2",
"    </a>",
"    ). Voltage in high-tension power lines is greater than 100,000 V, while the typical voltage delivered to homes is either 110 V (North America) or 220 V (Europe and Asia). In contrast, lightning strikes are associated with a potential difference between the atmosphere and the ground in excess of 10 million volts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, there are four classes of electrical injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classic injury pattern develops when the body becomes part of a circuit and is usually associated with entrance and exit wounds. These wounds generally do not help predict the path of the current, and the skin findings can significantly",
"      <strong>",
"       underestimate",
"      </strong>",
"      the degree of internal thermal injury.",
"     </li>",
"     <li>",
"      Flash (or arc) burns occur when the current arc strikes the skin, but does not enter the body.",
"     </li>",
"     <li>",
"      Flame injuries from clothing catching fire in the presence of an electrical source.",
"     </li>",
"     <li>",
"      Lightning injury is caused by a DC current exposure that lasts from",
"      <span class=\"nowrap\">",
"       1/10",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       1/1000",
"      </span>",
"      of a second, but often has voltages that exceed 10 million V [",
"      <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/4,9,36\">",
"       4,9,36",
"      </a>",
"      ]. Peak temperature within a bolt of lightning rises within milliseconds to 30,000 Kelvin (five times hotter than the sun), generating a shock wave of up to 20 atmospheres induced by the rapid heating of the surrounding air [",
"      <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/9,36,37\">",
"       9,36,37",
"      </a>",
"      ]. This shock wave then can be transmitted through the body and result in mechanical trauma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the variability of tissue resistance, surface area, and volume of tissue exposed, it is extremely difficult to predict the actual course of current flow and to infer the type and extent of injuries to internal organs. Careful clinical assessment, recognizing that surface findings may underestimate the extent of tissue damage or necrosis, should be used to guide management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ORGAN INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of electrical injuries range from mild superficial skin burns to severe multiorgan dysfunction and death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiac",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall estimate of arrhythmia following electrical injury is approximately 15 percent; most of these are benign and occur within the first few hours of hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. However, acute electrical cardiac injury can result in sudden cardiac arrest due to asystole (usually with DC current or lightning) or ventricular fibrillation (AC current) prior to hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/40\">",
"     40",
"    </a>",
"    ]. Ventricular fibrillation is the most common fatal arrhythmia, occurring in up to 60 percent of patients in whom the electrical current pathway travels from one hand to the other [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/3,41\">",
"     3,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link&amp;anchor=H8#H8\">",
"     \"Advanced cardiac life support (ACLS) in adults\", section on 'Ventricular fibrillation and pulseless ventricular tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spontaneous return of sinus rhythm has been noted after asystole in cases of electrical injury, but because respiratory paralysis lasts longer, the rhythm may degenerate to ventricular fibrillation due to hypoxia. Atrial dysrhythmias, first and second-degree heart block, and bundle branch blocks have been noted as well [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/3,39\">",
"     3,39",
"    </a>",
"    ]. It is postulated that the anterior location of the right coronary artery leaves the sinus and AV nodal arteries more vulnerable. Changes in the ST segment and T wave, as well as conduction disturbances, generally resolve without specific treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18308?source=see_link\">",
"     \"Basic approach to delayed intraventricular conduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Damage to the myocardium is uncommon, but can occur as a result of heat injury or myocardial contusion resulting from the shock wave of a lightning strike. Cardiac contusion is the most common pathologic cardiac finding, while myocardial infarction is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/42\">",
"     42",
"    </a>",
"    ]. Other rare cardiac manifestations include coronary spasm and myocardial rupture due to coagulation necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/37,43-47\">",
"     37,43-47",
"    </a>",
"    ]. The evaluation and management of cardiac contusion and the clinical manifestations of myocardial rupture are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27385?source=see_link\">",
"     \"Cardiac injury from blunt trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link\">",
"     \"Mechanical complications of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis may result from massive tissue necrosis and can be complicated by pigment-induced acute kidney injury. In addition, hypovolemia due to extravascular extravasation of fluid can lead to prerenal azotemia and acute tubular necrosis. The diagnosis of these complications is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link&amp;anchor=H11512155#H11512155\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Causes of rhabdomyolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Damage to both the central and peripheral nervous systems can occur after electrical injury. Manifestations may include loss of consciousness, weakness or paralysis, respiratory depression, autonomic dysfunction, and memory disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Sensory and motor findings due to peripheral nerve damage are common. Unless the patient attempts to ambulate, lower-extremity weakness may go undiagnosed initially. Of note, the deficits may be &ldquo;patchy&rdquo; with the sensory deficits not corresponding to the motor findings. The clinical manifestations of neurologic damage from high-voltage exposures may be delayed for days to months after the injury.",
"   </p>",
"   <p>",
"    Keraunoparalysis is a temporary paralysis specific to lightning injuries that is characterized by blue, mottled, and pulseless extremities (lower more commonly than upper). These findings are felt to be secondary to vascular spasm and often resolve within hours but can be permanent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients hit by lightning may present with pupils that are fixed and dilated or asymmetric due to autonomic dysfunction. As a result, fixed, dilated, or asymmetric pupils should",
"    <strong>",
"     not",
"    </strong>",
"    be used as a reason to stop resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/9\">",
"     9",
"    </a>",
"    ]. Complications of lightning strikes can include hypoxic encephalopathy, intracerebral hemorrhage, cerebral infarction, and spinal fractures have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Cardiopulmonary resuscitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Cataracts, hyphema, vitreous hemorrhage, and optic nerve injury can occur, particularly following lightning injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/9,50\">",
"     9,50",
"    </a>",
"    ]. In addition, 50 to 80 percent of patients struck by lightning sustain ruptured tympanic membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/42,54,55\">",
"     42,54,55",
"    </a>",
"    ]. Sensorineural hearing loss, tinnitus, vertigo, and injury to the facial nerve have all been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/54,56\">",
"     54,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=see_link\">",
"     \"Cataract in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=see_link\">",
"     \"Traumatic hyphema: Clinical features and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26888?source=see_link&amp;anchor=H9#H9\">",
"     \"Approach to the adult with acute persistent visual loss\", section on 'Vitreous hemorrhage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=see_link\">",
"     \"Ear barotrauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial, partial-thickness, and full-thickness thermal burns can occur following electrical injury. It has been estimated that exposure to 20 to 35 mA per mm2 of skin surface for 20 seconds raises the skin temperature to 50&ordm;C, leading to blistering and swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/57\">",
"     57",
"    </a>",
"    ]. Seventy-five mA per mm2 for the same period raises the temperature to 90&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/34\">",
"     34",
"    </a>",
"    ], and may cause more severe burns and charring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=see_link\">",
"     \"Treatment of minor thermal burns\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a postmortem study of 220 fatal electrical injuries, 57 percent of low-voltage and 96 percent of high-voltage victims had visible electrical burns [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/35\">",
"     35",
"    </a>",
"    ]. Burns are most common at the site of electrical contact and at places in contact with the ground at the time of injury. The degree of external injury",
"    <strong>",
"     cannot",
"    </strong>",
"    be used to determine the extent of internal damage, especially with low-voltage injuries. Seemingly minor surface burns may coexist with massive muscle coagulation and necrosis, as well as internal organ injury. Patients with cranial burns or leg burns from lightning are at higher risk for death than others struck by lightning, possibly because more current has passed directly through the body [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A unique type of burn seen with electrical injury is the &ldquo;kissing burn&rdquo;. This occurs at flexor creases, where the flexor surfaces adjacent to a joint touch.",
"   </p>",
"   <p>",
"    Oral burns can occur in young children from sucking or chewing on extension cords. Delayed hemorrhage from the labial artery may occur when the eschar separates, sometimes days after the injury. Cosmetic defects may also occur, particularly when the commissure is involved.",
"   </p>",
"   <p>",
"    The incidence of superficial surface burns is high in victims of lightning injury, but deep burns are unusual [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/50\">",
"     50",
"    </a>",
"    ]. One series of patients following lightning strike noted an 89 percent incidence of burns, but only 5 percent were deep [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/58\">",
"     58",
"    </a>",
"    ]. The low incidence of deep burns is in part due to the short duration of contact and the \"flashover effect\", which occurs when the current travels on the skin surface and is discharged to the ground. This can result in the formation of branching cutaneous &ldquo;feather&rdquo; lesions, also called Lichtenberg figures, which fade rapidly but are pathognomonic of lightning injury (",
"    <a class=\"graphic graphic_picture graphicRef69684 \" href=\"UTD.htm?13/58/14240\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Musculoskeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because bone has the highest resistance of any body tissue, it generates the greatest amount of heat when exposed to an electrical current. Thus, the areas of greatest thermal injury are often the deep tissue surrounding long bones, potentially resulting in periosteal burns, destruction of bone matrix, and osteonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to burn-related injuries, bones can fracture from falls, blast injuries, or under the stress of repetitive tetanic muscle contractions. It is reasonable to obtain imaging studies of the cervical spine to assess for fracture in patients with significant electrical injuries or an altered mental status.",
"   </p>",
"   <p>",
"    Deep electrothermal injury can result in tissue necrosis and edema and the development of acute compartment syndrome, leading to rhabdomyolysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    visceral injury. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Myoglobinuria'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=see_link\">",
"     \"Crush-related acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Vascular, coagulation system, and other injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular injury can result from an acute compartment syndrome or the electrical coagulation of small blood vessels. Such vascular trauma is more common following electrical than lightning-related injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed arterial thrombosis as well as aneurysm formation and rupture have been reported following electrical injury and are due to medial coagulation and necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/41,60-62\">",
"     41,60-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Damage to internal organs, including the lungs, stomach, small intestine, and colon, is uncommon. When abdominal involvement does occur, it can be complicated by fistula formation, perforation, secondary polymicrobial infection, sepsis, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who fall or are thrown as a result of a severe electrical exposure may sustain severe injuries and must be carefully evaluated. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Trauma resuscitation and neurologic evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69315709\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting for medical care following a significant electrical exposure are susceptible to a wide range of injuries, including those sustained from falling or being thrown, and should be carefully examined, with particular attention paid to the organ systems most often affected. Following severe electrical exposures, some injuries may not be apparent initially and frequent reassessment is essential. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Organ involvement'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Important areas to assess include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airway, breathing, and circulation",
"     </li>",
"     <li>",
"      Cardiovascular function: assess cardiac rhythm; examine pulses",
"     </li>",
"     <li>",
"      Skin: Inspect for burns; look for blisters, charred skin, and other lesions; pay attention to skin creases, areas around joints, and the mouth (particularly in young children)",
"     </li>",
"     <li>",
"      Neurologic function: assess mental status, pupillary function, strength and motor function, and sensation",
"     </li>",
"     <li>",
"      Ophthalmologic: assess visual acuity; inspect the eyes, including a funduscopic examination",
"     </li>",
"     <li>",
"      Ear, nose, and throat: inspect the tympanic membranes; assess hearing",
"     </li>",
"     <li>",
"      Musculoskeletal: inspect and palpate for signs of injury (eg, fracture, acute compartment syndrome), and be certain to examine the spine",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cardiopulmonary resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged cardiopulmonary resuscitation (CPR) should be undertaken following electrical injury regardless of the initial rhythm, since most victims are young and good outcomes have been noted even among patients with asystole [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/3,65\">",
"     3,65",
"    </a>",
"    ]. For this reason and because patients who do not sustain cardiac arrest generally survive without intervention, usual triage priorities are reversed if multiple victims are present: patients without signs of life are treated first [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/3,50,55,58\">",
"     3,50,55,58",
"    </a>",
"    ]. The treatment for particular arrhythmias is unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=see_link\">",
"     \"Guidelines for pediatric advanced life support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=see_link\">",
"     \"Prehospital care of the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients can have spontaneous cardiac activity but paralysis of the respiratory muscles. Prompt restoration of gas exchange via a secure airway may prevent secondary cardiac and neurologic dysfunction or death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=see_link\">",
"     \"Advanced emergency airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lightning injury can result in clinical signs typically associated with severe brain injury (eg, fixed and dilated pupils) but which may not accurately reflect the patient&rsquo;s neurologic status. Therefore, prolonged CPR may be indicated and clinical judgement should be used to determine the appropriate duration of resuscitative efforts. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Neurologic'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=see_link&amp;anchor=H8#H8\">",
"     \"Outcome of sudden cardiac arrest\", section on 'Factors affecting out-of-hospital SCA outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Trauma resuscitation and neurologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient who suffers a serious electrical burn or lightning strike has sustained significant trauma. Appropriate trauma resuscitation should be performed, beginning with a rapid assessment of the airway and cardiopulmonary status. Coexisting smoke inhalation or airway burns must be excluded. Cervical spine immobilization and clearance are necessary, and tetanus prophylaxis should be administered. Coma or neurologic deficit, including alterations in mental status, should prompt brain and spine imaging. A careful secondary survey is needed once the initial resuscitation is complete. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cardiac injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The survivor of a high-energy (&gt;1000 V) injury should be evaluated with and electrocardiogram (ECG) and have cardiac and hemodynamic monitoring due to the high incidence of arrhythmia and autonomic dysfunction, especially if there have been arrhythmias in the field or emergency department, loss of consciousness, or if the initial ECG is abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/50\">",
"     50",
"    </a>",
"    ]. In many cases, telemetry is adequate. Patients with signs of instability (eg, recurrent arrhythmia or hypotension) require more intensive monitoring.",
"   </p>",
"   <p>",
"    Serum CK-MB measurements and ECG changes are poor measures of myocardial injury following electrical trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/37,43-47,50\">",
"     37,43-47,50",
"    </a>",
"    ]. The diagnostic and prognostic value of cardiac troponin has not been formally studied in this setting. However, some researchers believe that troponin-I levels and echocardiography can detect myocardial injury after electric shock [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/66\">",
"     66",
"    </a>",
"    ]. The best method to assess myocardial damage following electrical injury remains uncertain and is best determined in consultation with a cardiologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Fluid resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with soft tissue injuries from a severe electrical exposure often require aggressive IV fluid replacement, especially if there are signs of muscle necrosis; those with lightning injuries typically require less volume than patients with thermal burns [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/9\">",
"     9",
"    </a>",
"    ]. Parkland and similar formulas used for fluid resuscitation following thermal burns should",
"    <strong>",
"     not",
"    </strong>",
"    be used in victims of electrical injuries, since surface burns may grossly underestimate the extent of injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link&amp;anchor=H10#H10\">",
"     \"Emergency care of moderate and severe thermal burns in adults\", section on 'Fluid resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to fluid resuscitation is similar to that used for the prevention of acute kidney injury from heme pigments (ie, myoglobinuria) and is discussed separately. Fluid resuscitation for patients with severe soft tissue injuries is comparable to that used for major crush injuries. Given the risk of hyperkalemia, IV fluids containing potassium should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link&amp;anchor=H25398978#H25398978\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=see_link\">",
"     \"Crush-related acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute hypotension should prompt a search for thoracic or intraabdominal bleeding secondary to blunt trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link\">",
"     \"Initial evaluation and management of shock in adult trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Large fluid shifts can occur following electrical injury, and clinicians should pay close attention to volume status and electrolytes throughout the course of management. Physiologic measures, including heart rate, blood pressure, and urine output, are useful in guiding resuscitation. Central venous pressure monitoring may be beneficial in patients with more severe injuries. Urine output in adults should be maintained at over 100 mL per hour (for young children, a goal of approximately 1.5 to 2",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour is reasonable); serum electrolyte concentrations, particularly potassium, should be measured approximately every two to four hours early during management, depending upon the prior value, renal function, and clinical status.",
"   </p>",
"   <p>",
"    The combination of aggressive fluid repletion and restrictive surface burns can lead to the development of increased intraabdominal pressure and the abdominal compartment syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cerebral salt wasting has been reported as a complication of lightning-related electrical injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8567?source=see_link\">",
"     \"Cerebral salt-wasting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Myoglobinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be monitored for the development of acute compartment syndrome, rhabdomyolysis, and acute kidney injury. The goal should be to maintain adequate urine output to minimize intratubular cast formation until pigment has cleared from the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. However, in patients who develop acute kidney injury and are oliguric or anuric, care must be taken to avoid massive fluid overload from excessive fluid administration. Recognition and management of acute compartment syndrome and the prevention and treatment of myoglobinuria are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radionuclide imaging with technetium-99 has been used to identify nonviable muscle following severe electrical injury; however, it is not clear if the results have an impact on treatment decisions or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. Persistent myoglobinuria may necessitate amputation of the injured extremity in some cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12186?source=see_link\">",
"     \"Severe extremity injury in the adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H871295\">",
"    <span class=\"h2\">",
"     Skin wounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, wounds are treated in a similar manner to flame or other thermal burns. However, Parkland and similar formulas used for fluid resuscitation following thermal burns should",
"    <strong>",
"     not",
"    </strong>",
"    be used in victims of electrical injuries, since surface burns may significantly underestimate the extent of injury. Patients with burns may require transfer to a burn unit and treatment with fasciotomy, escharotomy, extensive skin reconstruction, or limb amputation. Topical antibiotic prophylaxis is indicated for non-superficial burns. The value of prophylaxis with intravenous antibiotics is controversial. Some physicians give penicillin to cover Clostridial species since myonecrosis has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50175484\">",
"    <span class=\"h2\">",
"     Gastrointestinal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal injury is uncommon, but persistent ileus, abdominal pain, or tenderness should prompt abdominal imaging and surgical consultation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/9\">",
"     9",
"    </a>",
"    ]. Injury to abdominal organs, possibly caused by a vascular insult, can occur and may require laparotomy. As with mesenteric ischemia, symptoms and signs of injury may be delayed and diagnosis can be difficult.",
"   </p>",
"   <p>",
"    Patients have a greater chance of developing gastric ulcers following electrical burns (Curlings ulcers) than with other burns [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/4,9,71\">",
"     4,9,71",
"    </a>",
"    ]. Therefore, it is prudent to provide prophylactic therapy, particularly in patients with severe burns and those who cannot or are not permitted to take food by mouth (NPO). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link\">",
"     \"Stress ulcer prophylaxis in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;After stabilization, careful otologic and audiometric examinations may reveal injuries that are amenable to delayed repair [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/4,9,58\">",
"     4,9,58",
"    </a>",
"    ]. Ophthalmologic evaluation is warranted because of the potential for delayed development of cataracts, particularly following lightning injury [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/9\">",
"     9",
"    </a>",
"    ]. Cataracts generally develop several days after injury, though there may be a lag of up to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Early institution of physical therapy may prevent deterioration in functional status, and psychiatric consultation may be required for patients who develop behavioral disturbances or posttraumatic stress disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/52,73\">",
"     52,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=see_link\">",
"     \"Pharmacotherapy for posttraumatic stress disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168942132\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;No clear guidelines exist about what studies to obtain following electrical injury and to a large degree this must be determined clinically on a case by case basis. For patients who warrant observation or admission to the hospital following such an injury, we generally obtain the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Electrocardiogram",
"     </li>",
"     <li>",
"      Basic serum electrolytes (including potassium and calcium)",
"     </li>",
"     <li>",
"      Creatine phosphokinase (to detect muscle injury)",
"     </li>",
"     <li>",
"      Serum troponin",
"     </li>",
"     <li>",
"      Basic blood counts",
"     </li>",
"     <li>",
"      Renal function studies (creatinine and BUN)",
"     </li>",
"     <li>",
"      Radiographic studies of any region we suspect may have been injured.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of troponin to assess cardiac injury is uncertain and should be discussed with cardiology. We obtain repeat studies as clinically indicated. For asymptomatic patients with a low-voltage exposure and an unremarkable physical examination, diagnostic testing is generally not necessary. (See",
"    <a class=\"local\" href=\"#H16371443\">",
"     'Disposition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16371443\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severely injured patients are admitted to an intensive care setting. Patients with significant electrical burns should generally be transferred to a burn center when stable.",
"   </p>",
"   <p>",
"    When exposure to high-voltage (&gt;1000 V) is suspected, 12 to 24 hours of cardiac monitoring is prudent despite the apparent absence of injury. Additional indications for monitoring include a history of cardiac disease, active chest pain, or a documented loss of consciousness or arrhythmia in a patient exposed to lower-voltage.",
"   </p>",
"   <p>",
"    Patients who are asymptomatic after a low-voltage exposure with a normal physical examination do not require ancillary diagnostic tests and can be reassured and discharged [",
"    <a class=\"abstract\" href=\"UTD.htm?4/19/4410/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients with mild persistent symptoms or minor cutaneous burns and a normal ECG and urinalysis (no hemoglobinuria) can be observed for a few hours and discharged with appropriate follow-up based upon the severity of their wounds and any comorbidities. Obstetric consultation for pregnant patients is reasonable. Placental abruption may be associated with minor trauma, including electrical injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/51/33586?source=see_link\">",
"       \"Patient information: Electrical burns (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H871134\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrical injuries are relatively common and often preventable. Lightning injuries comprise a small subset of electrical injuries. Injuries from electrical weapons are increasing as these devices become more widely used, but serious injuries resulting from their use are rare. The direct effect of electrical current, conversion of electrical to thermal energy, and blunt mechanical trauma can all result in tissue destruction and organ dysfunction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Electrical weapons'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Physics of electricity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of electrical injuries range from mild superficial skin burns to severe multiorgan dysfunction and death, depending upon the intensity and the duration of exposure. Following severe electrical exposures, some injuries may not be apparent initially and frequent reassessment is essential. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Organ involvement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H69315709\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The organ systems most often affected include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cardiac &ndash; Arrhythmia can occur; myocardial injury is uncommon. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cardiac'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin &ndash; Burns can range from superficial to full-thickness. Do",
"      <strong>",
"       not",
"      </strong>",
"      use surface injuries to gauge the extent of internal injury, which may be extensive despite little skin involvement. Deep injuries are less common with a lightning strike. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Skin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Musculoskeletal &ndash; Severe thermal injury can result in periosteal burns, destruction of bone matrix, and osteonecrosis; massive soft tissue and muscle injury can occur and may lead to rhabdomyolysis or acute compartment syndrome. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Musculoskeletal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal &ndash; Rhabdomyolysis may lead to pigment-induced acute kidney injury. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Renal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic &ndash; Injury to the central and peripheral nervous system can occur; manifestations can range from coma to memory dysfunction to autonomic dysfunction to mixed peripheral motor and sensory deficits (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Neurologic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vascular &ndash; Vascular injury can occur and may range from coagulation of small veins to thrombosis of major arteries; signs of vascular injury can be delayed. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Vascular, coagulation system, and other injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other &ndash; Patients who fall or are thrown following a severe electrical exposure can sustain severe traumatic injuries; cataracts, hyphema, and vitreous hemorrhage can occur; tympanic membrane rupture is common following a lightning strike.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prolonged cardiopulmonary resuscitation is appropriate for many patients who sustain a sudden cardiac arrest (SCA) following severe electrical injury because they are often young and outcomes are generally better than SCA from other causes. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Cardiopulmonary resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A trauma evaluation and appropriate resuscitation, beginning with a rapid assessment of the airway and cardiopulmonary status, should be performed for any patient with a severe electrical exposure. Cervical spine immobilization and assessment is necessary. Coma or neurologic deficit, including alterations in mental status, should prompt brain and spine imaging. A careful secondary survey is needed once the initial resuscitation is complete. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Trauma resuscitation and neurologic evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"       \"Initial management of trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The survivor of a high-energy (&gt;1000 V) injury should have cardiac and hemodynamic monitoring due to the high incidence of arrhythmia and autonomic dysfunction, especially if there have been arrhythmias in the field or emergency department, loss of consciousness, or if the initial ECG is abnormal. In most cases, telemetry is adequate. Patients with signs of instability (eg, recurrent arrhythmia or hypotension) require more intensive monitoring. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Cardiac injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with significant electrical injuries should be monitored for the development of acute compartment syndrome, rhabdomyolysis, and acute kidney injury. Such patients often require aggressive IV fluid replacement, especially if there are signs of muscle necrosis; those with lightning injuries typically require less volume than patients with thermal burns. The approach to fluid resuscitation is similar to that used for the prevention of kidney injury from heme pigments (ie, myoglobinuria) and is discussed separately. Fluid resuscitation for patients with severe electrical injuries is comparable to that used for major crush injuries. Given the risk of hyperkalemia, IV fluids containing potassium should be avoided. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link&amp;anchor=H25398978#H25398978\">",
"       \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Prevention'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H19\">",
"       'Fluid resuscitation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Myoglobinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin wounds from electrical injuries are treated in a similar manner to flame or other thermal burns. Importantly, Parkland and similar formulas used for fluid resuscitation following thermal burns should",
"      <strong>",
"       not",
"      </strong>",
"      be applied to electrical injuries, since surface burns may grossly underestimate the extent of injury. (See",
"      <a class=\"local\" href=\"#H871295\">",
"       'Skin wounds'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrical weapons do not cause cardiac arrhythmias or other dangerous injuries when used appropriately by law enforcement officers and exposure lasts 15 seconds or less. Prolonged observation and diagnostic testing are",
"      <strong>",
"       not",
"      </strong>",
"      necessary in such patients who are otherwise asymptomatic and alert following the exposure. The disposition of patients with an electrical exposure is discussed in the text. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Electrical weapons'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16371443\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93020802\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/1\">",
"      Baxter CR, Waeckerle JF. Emergency treatment of burn injury. Ann Emerg Med 1988; 17:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/2\">",
"      Cooper MA. Electrical and lightning injuries. Emerg Med Clin North Am 1984; 2:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/3\">",
"      Spies C, Trohman RG. Narrative review: Electrocution and life-threatening electrical injuries. Ann Intern Med 2006; 145:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/4\">",
"      Browne BJ, Gaasch WR. Electrical injuries and lightning. Emerg Med Clin North Am 1992; 10:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/5\">",
"      Skoog T. Electrical injuries. J Trauma 1970; 10:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/6\">",
"      Cawley JC, Homce GT. Occupational electrical injuries in the United States, 1992-1998, and recommendations for safety research. J Safety Res 2003; 34:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/7\">",
"      Baker MD, Chiaviello C. Household electrical injuries in children. Epidemiology and identification of avoidable hazards. Am J Dis Child 1989; 143:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/8\">",
"      Rabban JT, Blair JA, Rosen CL, et al. Mechanisms of pediatric electrical injury. New implications for product safety and injury prevention. Arch Pediatr Adolesc Med 1997; 151:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/9\">",
"      Jain S, Bandi V. Electrical and lightning injuries. Crit Care Clin 1999; 15:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/10\">",
"      Taylor AJ, McGwin G Jr, Davis GG, et al. Occupational electrocutions in Jefferson County, Alabama. Occup Med (Lond) 2002; 52:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/11\">",
"      Wick R, Gilbert JD, Simpson E, Byard RW. Fatal electrocution in adults--a 30-year study. Med Sci Law 2006; 46:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/12\">",
"      Zafren K, Durrer B, Herry JP, et al. Lightning injuries: prevention and on-site treatment in mountains and remote areas. Official guidelines of the International Commission for Mountain Emergency Medicine and the Medical Commission of the International Mountaineering and Climbing Federation (ICAR and UIAA MEDCOM). Resuscitation 2005; 65:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/13\">",
"      Centers for Disease Control and Prevention (CDC). Lightning-associated injuries and deaths among military personnel--United States, 1998-2001. MMWR Morb Mortal Wkly Rep 2002; 51:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/14\">",
"      O'Keefe Gatewood M, Zane RD. Lightning injuries. Emerg Med Clin North Am 2004; 22:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/15\">",
"      Lopez, RE, Holle, RL. The underreporting of lightning injuries and death in Colorado. Bull Am Meteor Soc 1995; 74:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/16\">",
"      Ritenour AE, Morton MJ, McManus JG, et al. Lightning injury: a review. Burns 2008; 34:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/17\">",
"      Centers for Disease Control and Prevention (CDC). Lightning-associated deaths--United States, 1980-1995. MMWR Morb Mortal Wkly Rep 1998; 47:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/18\">",
"      Duclos PJ, Sanderson LM. An epidemiological description of lightning-related deaths in the United States. Int J Epidemiol 1990; 19:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/19\">",
"      L&oacute;pez RE, Holle RL. Demographics of lightning casualties. Semin Neurol 1995; 15:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/20\">",
"      Bleetman A, Steyn R, Lee C. Introduction of the Taser into British policing. Implications for UK emergency departments: an overview of electronic weaponry. Emerg Med J 2004; 21:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/21\">",
"      Fish RM, Geddes LA. Effects of stun guns and tasers. Lancet 2001; 358:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/22\">",
"      Vilke GM, Bozeman WP, Chan TC. Emergency department evaluation after conducted energy weapon use: review of the literature for the clinician. J Emerg Med 2011; 40:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/23\">",
"      Pasquier M, Carron PN, Vallotton L, Yersin B. Electronic control device exposure: a review of morbidity and mortality. Ann Emerg Med 2011; 58:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/24\">",
"      Bozeman WP, Teacher E, Winslow JE. Transcardiac conducted electrical weapon (TASER) probe deployments: incidence and outcomes. J Emerg Med 2012; 43:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/25\">",
"      Gardner AR, Hauda WE 2nd, Bozeman WP. Conducted electrical weapon (TASER) use against minors: a shocking analysis. Pediatr Emerg Care 2012; 28:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/26\">",
"      Ordog GJ, Wasserberger J, Schlater T, Balasubramanium S. Electronic gun (Taser) injuries. Ann Emerg Med 1987; 16:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/27\">",
"      Kim PJ, Franklin WH. Ventricular fibrillation after stun-gun discharge. N Engl J Med 2005; 353:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/28\">",
"      Kornblum RN, Reddy SK. Effects of the Taser in fatalities involving police confrontation. J Forensic Sci 1991; 36:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/29\">",
"      Mehl LE. Electrical injury from Tasering and miscarriage. Acta Obstet Gynecol Scand 1992; 71:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/30\">",
"      Dalziel, CF. The threshold of perception currents. Trans Am Inst Electrical Engineering 1954; 73:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/31\">",
"      Geddes LA, Baker LE. The specific resistance of biological material--a compendium of data for the biomedical engineer and physiologist. Med Biol Eng 1967; 5:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/32\">",
"      Hawkes, GR. The sensory range of electrical stimulation of the skin. Am J Psychol 1960; 73:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/33\">",
"      Lee RC, Zhang D, Hannig J. Biophysical injury mechanisms in electrical shock trauma. Annu Rev Biomed Eng 2000; 2:477.",
"     </a>",
"    </li>",
"    <li>",
"     Cabanes J. Physiologic effects of electric currents on living organisms, more particularly humans. In: Electric Shock Safety Criteria: Proceedings of the First International Symposium on Electric Shock Safety Criteria, Bridges JE, Ford CL, Sherman IA, Valnberg M.  (Eds), Pergamon Press, Tarrytown 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/35\">",
"      Wright RK, Davis JH. The investigation of electrical deaths: a report of 220 fatalities. J Forensic Sci 1980; 25:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/36\">",
"      Krider EP, Uman MA. Cloud-to-ground lightning: mechanisms of damage and methods of protection. Semin Neurol 1995; 15:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/37\">",
"      Lichtenberg R, Dries D, Ward K, et al. Cardiovascular effects of lightning strikes. J Am Coll Cardiol 1993; 21:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/38\">",
"      Purdue GF, Hunt JL. Electrocardiographic monitoring after electrical injury: necessity or luxury. J Trauma 1986; 26:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/39\">",
"      Das KM. Electrocardiographic changes following electric shock. Indian J Pediatr 1974; 41:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/40\">",
"      LOWN B, NEUMAN J, AMARASINGHAM R, BERKOVITS BV. Comparison of alternating current with direct electroshock across the closed chest. Am J Cardiol 1962; 10:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/41\">",
"      DiVincenti FC, Moncrief JA, Pruitt BA Jr. Electrical injuries: a review of 65 cases. J Trauma 1969; 9:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/42\">",
"      Wetli CV. Keraunopathology. An analysis of 45 fatalities. Am J Forensic Med Pathol 1996; 17:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/43\">",
"      Ku CS, Lin SL, Hsu TL, et al. Myocardial damage associated with electrical injury. Am Heart J 1989; 118:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/44\">",
"      Xenopoulos N, Movahed A, Hudson P, Reeves WC. Myocardial injury in electrocution. Am Heart J 1991; 122:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/45\">",
"      McBride JW, Labrosse KR, McCoy HG, et al. Is serum creatine kinase-MB in electrically injured patients predictive of myocardial injury? JAMA 1986; 255:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/46\">",
"      Kinney TJ. Myocardial infarction following electrical injury. Ann Emerg Med 1982; 11:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/47\">",
"      Kirchmer JT Jr, Larson DL, Tyson KR. Cardiac rupture following electrical injury. J Trauma 1977; 17:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/48\">",
"      Ramati A, Pliskin NH, Keedy S, et al. Alteration in functional brain systems after electrical injury. J Neurotrauma 2009; 26:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/49\">",
"      Cherington M. Spectrum of neurologic complications of lightning injuries. NeuroRehabilitation 2005; 20:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/50\">",
"      Davis C, Engeln A, Johnson E, et al. Wilderness medical society practice guidelines for the prevention and treatment of lightning injuries. Wilderness Environ Med 2012; 23:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/51\">",
"      ten Duis HJ, Klasen HJ, Reenalda PE. Keraunoparalysis, a 'specific' lightning injury. Burns Incl Therm Inj 1985; 12:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/52\">",
"      Cherington M. Neurologic manifestations of lightning strikes. Neurology 2003; 60:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/53\">",
"      Caksen H, Yuca SA, Demirtas I, et al. Right thalamic hemorrhage resulting from high-voltage electrical injury: a case report. Brain Dev 2004; 26:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/54\">",
"      Patten BM. Lightning and electrical injuries. Neurol Clin 1992; 10:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/55\">",
"      Glunci�� I, Roje Z, Glunci�� V, Poljak K. Ear injuries caused by lightning: report of 18 cases. J Laryngol Otol 2001; 115:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/56\">",
"      Liew L, Morrison GA. Bilateral hearing loss following electrocution. J Laryngol Otol 2006; 120:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/57\">",
"      ten Duis HJ. Acute electrical burns. Semin Neurol 1995; 15:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/58\">",
"      Cooper MA. Lightning injuries: prognostic signs for death. Ann Emerg Med 1980; 9:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/59\">",
"      Vega LA, de Quevedo Garc&iacute;a JA, Santamari&aacute; CT, Porras MC. Clinical picture: An unwanted tattoo. Lancet 2001; 358:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/60\">",
"      Moncrief JA, Pruitt BA Jr. Electric injury. Postgrad Med 1970; 48:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/61\">",
"      Hunt JL, McManus WF, Haney WP, Pruitt BA Jr. Vascular lesions in acute electric injuries. J Trauma 1974; 14:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/62\">",
"      D'Attellis N, Luong V, Grinda JM. A shocking injury. Lancet 2004; 363:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/63\">",
"      Haberal M, U&ccedil;ar N, Bayraktar U, et al. Visceral injuries, wound infection and sepsis following electrical injuries. Burns 1996; 22:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/64\">",
"      Rijhwani A, Sunil I. Colonic fistula complicating electric burns--a case report. J Pediatr Surg 2003; 38:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/65\">",
"      Schwarz ES, Barra M, Liao MM. Successful resuscitation of a patient in asystole after a TASER injury using a hypothermia protocol. Am J Emerg Med 2009; 27:515.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/66\">",
"      Celebi A, Gulel O, Cicekcioglu H, et al. Myocardial infarction after an electric shock: a rare complication. Cardiol J 2009; 16:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/67\">",
"      Emet M, Caner I, Cakir M, et al. Lightning injury may cause abrupt cerebral salt wasting syndrome. Am J Emerg Med 2010; 28:640.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/68\">",
"      Affleck DG, Edelman L, Morris SE, Saffle JR. Assessment of tissue viability in complex extremity injuries: utility of the pyrophosphate nuclear scan. J Trauma 2001; 50:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/69\">",
"      Sayman HB, Urgancioglu I, Uslu I, Kapicioglu T. Prediction of muscle viability after electrical burn necrosis. Clin Nucl Med 1992; 17:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/70\">",
"      Hammond J, Ward CG. The use of Technetium-99 pyrophosphate scanning in management of high voltage electrical injuries. Am Surg 1994; 60:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/71\">",
"      Apfelberg DB, Masters FW, Robinson DW. Pathophysiology and treatment of lightning injuries. J Trauma 1974; 14:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/72\">",
"      Strasser EJ, Davis RM, Menchey MJ. Lightning injuries. J Trauma 1977; 17:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/19/4410/abstract/73\">",
"      Yarnell PR, Lammertse DP. Neurorehabilitation of lightning and electrical injuries. Semin Neurol 1995; 15:391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 175 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_19_4410=[""].join("\n");
var outline_f4_19_4410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H871134\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14469301\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Lightning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ELECTRICAL WEAPONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHYSICS OF ELECTRICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLASSIFICATION OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ORGAN INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Musculoskeletal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Vascular, coagulation system, and other injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69315709\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cardiopulmonary resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Trauma resuscitation and neurologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cardiac injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Fluid resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Myoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H871295\">",
"      Skin wounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50175484\">",
"      Gastrointestinal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H168942132\">",
"      DIAGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16371443\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H871134\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93020802\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/175\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/175|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/58/14240\" title=\"picture 1\">",
"      Cutaneous lightning injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/175|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/35/32315\" title=\"table 1\">",
"      Effect of electrical current",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/11/25788\" title=\"table 2\">",
"      High vs low voltage injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26888?source=related_link\">",
"      Approach to the adult with acute persistent visual loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18308?source=related_link\">",
"      Basic approach to delayed intraventricular conduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27385?source=related_link\">",
"      Cardiac injury from blunt trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8567?source=related_link\">",
"      Cerebral salt-wasting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=related_link\">",
"      Crush-related acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35397?source=related_link\">",
"      Ear barotrauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39545?source=related_link\">",
"      Evaluation and management of the cardiovascular complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=related_link\">",
"      Guidelines for pediatric advanced life support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/474?source=related_link\">",
"      Methamphetamine intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=related_link\">",
"      Outcome of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37737?source=related_link\">",
"      Overview of electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/51/33586?source=related_link\">",
"      Patient information: Electrical burns (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33239?source=related_link\">",
"      Pharmacotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6425?source=related_link\">",
"      Phencyclidine (PCP) intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=related_link\">",
"      Prehospital care of the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12186?source=related_link\">",
"      Severe extremity injury in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22790?source=related_link\">",
"      Smoke inhalation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/10/38057?source=related_link\">",
"      Traumatic hyphema: Clinical features and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=related_link\">",
"      Treatment of minor thermal burns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_19_4411="Causes postprandial hypogly";
var content_f4_19_4411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of postprandial hypoglycemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Ackee fruit poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post Roux-en-Y gastric bypass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factitious hypoglycemia from insulin or sulfonylurea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gin and tonic hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary fructose intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin autoimmune hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Noninsulinoma pancreatogenous hypoglycemia syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic transplantation?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_19_4411=[""].join("\n");
var outline_f4_19_4411=null;
var title_f4_19_4412="Risk factors complicated UTI";
var content_f4_19_4412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors suggesting complicated urinary tract infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient demographics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male gender*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Advanced age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Comorbidities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunosuppression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of urinary tract infection in childhood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infection characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hospital-acquired infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uropathogen broadly resistant to antimicrobials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms for seven or more days before seeking care",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent antimicrobial use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recent urinary tract instrumentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Functional or anatomic abnormality of the urinary tract",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostatic hypertrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urethral stricture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of an indwelling urethral catheter, stent, nephrostomy tube or urinary diversion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Although urinary tract infections in men have traditionally been considered complicated because they generally occur in the elderly in the setting of urologic abnormalities, a small number of acute uncomplicated urinary tract infections do occur in healthy men between 15 and 50 years of age.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_19_4412=[""].join("\n");
var outline_f4_19_4412=null;
var title_f4_19_4413="Staging endometrial cancer I";
var content_f4_19_4413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Staging of endometrial cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        TNM categories",
"       </td>",
"       <td class=\"subtitle1\">",
"        FIGO* stages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TX",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Primary tumor cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        No evidence of primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Carcinoma in situ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T1",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        I",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Tumor confined to corpus uteri",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1a",
"       </td>",
"       <td class=\"sublist1\">",
"        IA",
"       </td>",
"       <td class=\"sublist_other\">",
"        Tumor limited to endometrium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1b",
"       </td>",
"       <td class=\"sublist1\">",
"        IB",
"       </td>",
"       <td class=\"sublist_other\">",
"        Tumor invades up to or less than one-half of the myometrium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1c",
"       </td>",
"       <td class=\"sublist1\">",
"        IC",
"       </td>",
"       <td class=\"sublist_other\">",
"        Tumor invades to more than one-half of the myometrium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T2",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        II",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Tumor invades cervix but does not extend beyond uterus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T2a",
"       </td>",
"       <td class=\"sublist1\">",
"        IIA",
"       </td>",
"       <td class=\"sublist_other\">",
"        Endocervical glandular involvement only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T2b",
"       </td>",
"       <td class=\"sublist1\">",
"        IIB",
"       </td>",
"       <td class=\"sublist_other\">",
"        Cervical stromal invasion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T3",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        III",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        Local and/or regional spread as specified in T3a, b, and/or N1 and FIGO IIIA, B, and C below",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T3a",
"       </td>",
"       <td class=\"sublist1\">",
"        IIIA",
"       </td>",
"       <td class=\"sublist_other\">",
"        Tumor involves uterine serosa and/or adnexa (direct extension or metastasis) [often termed stage IIIA2] and/or cancer cells in ascites or peritoneal washings [stage IIIA1]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T3b",
"       </td>",
"       <td class=\"sublist1\">",
"        IIIB",
"       </td>",
"       <td class=\"sublist_other\">",
"        Vaginal involvement (direct extension or metastasis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        IIIC",
"       </td>",
"       <td>",
"        Metastasis to the pelvic and/or para-aortic lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T4",
"       </td>",
"       <td>",
"        IVA",
"       </td>",
"       <td>",
"        Tumor invades bladder mucosa and/or bowel mucosa (Bullous edema is not sufficient to classify a tumor as T4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M1",
"       </td>",
"       <td>",
"        IVB",
"       </td>",
"       <td>",
"        Distant metastasis. (Excluding metastasis to vagina, pelvic serosa, or adnexa. Including metastasis to intra-abdominal lymph nodes other than para-aortic, and/or inguinal lymph nodes)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * FIGO: Federation Internationale de Gynecologie et d'Obstetrique.",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_19_4413=[""].join("\n");
var outline_f4_19_4413=null;
var title_f4_19_4414="Weight loss with orlistat";
var content_f4_19_4414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Weight loss with orlistat",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 298px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Weight loss (means &plusmn; SEM) during four years of treatment with orlistat plus lifestyle changes or placebo plus lifestyle changes in obese patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission of the American Diabetes Association. From: Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27:155. Copyright &copy; 2004; permission conveyed through Copyright Clearance Center, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_19_4414=[""].join("\n");
var outline_f4_19_4414=null;
var title_f4_19_4415="Metacarpal base fracture";
var content_f4_19_4415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fracture at the base of the second metacarpal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD52nkk81/3j9T3qIyP/ff8zU06/vn+p/nUO2rM0xhkk/vt+dIGkxne3/fRpxHarEcQOABSSDmsLZeY0oBdvzrorRX6lmP41RsrYAhq3IIsDjIraKsYVJoegkHdsn3rRtUYjlj09TTIIsnJFaVvHx0q0crdx0KsOhb86nmdlXG45+tOjjJ6ipJIMqDimTfqZxZ8Abmz7mrVurMwyzc8dakW1JI4q/b2wQc0A2PgVlXhjn61Ou4EfM350KnBqaNf8mmK4IWz945+tSpuHO4/nQi8dKlRefagLmnoUzR3ajJ545Nd1AxKDkmvPbNvLuI244Nd9ZNviU9M0GcmLMpD8ZxRHnd1P51aaPcOlQhTu6UE3J4vukZNcx4pRsBufzrqIV59KxPEsWbcnHShDTOKJbJ5P504Bv7x/OnuuD0oC+1BpzEWXyfmP50uWIwSfzp5TvSlcAkUBzEYLAg7jiu68OSFrKPnPFcSFyfrXY+GB/oo9BQTJmtcgk9TyKr4Oepq9KvA9arFDuHpQTcXBER5NcZ4lYm6ABPA9a7aVf3QFcT4iB+2fhQhxMUliOp/OmfNg8nH1qYqKjx1FBpcIdxnj+ZutekRZNiuSeBXnluD9ojJ9RXotv8A8eQz0xQTMybjIzyfzqqzN0GcVbuOCR0qKOPOARnNMVylqjmKybJI49a4SeVixyzdeua7LxRJtt9o6HiuKmGTxxSZcWVpZW/vH86iWVxyGOfrUjjJ7VGUy3pUj5jpfD05uFYAkkdeaszBw5O45/lWd4NyNTKjkFeRW1qg8udsDvTQX1MouzEqS3B9elFRkfOBz1ooLTPDtQsJIZ5OCRuNZ7Ifyr0O7hjkZzweTxWXcaLHcDMQG72rNwNo1u5x6J3rQs4ckdhVm70ea1IO0so71Ysrc46cVKjZlyqJq6LdpB09K1YIsqKhtY/lrSt0welaJHLKVyWCLPvV+FMAYqO3Tj+lXok2kcVRncWOPj6VYVR0AyaWOPgelSqmPegQJGMVP5eSPalRealVTTGR7Oe1SqnPAqRV9aeqc80CbGKpzjFShfwpyrwec1Iq8UCuCr39K7XRn328Z9q49F5wa6Xw5J+7ZCehoJZ0ij5aiKjdU8QyBTXX5qRIsI9qztdi3Wz/AErUiGe3NQajHuhYHuKEB506/MQR0pFGB1NWpotsjD0JphTHSmWQbeRQUyPepCv60gXrQMYE/Cup8Ln9zjPQ1zQQ966LwuTtYdweaBPY6Z1ytQFOatH7magUEufSkSJNxHXD66A122eld3cL8h4rg9cB+3PTWw0ZLrxx1poAzkjnvUpHY96FTgjFIsbFxMpx3r0S15sxn+7XnsQJlUEd69Fsh/oa/wC7QTIybgZYkmlgXmpZUy+O9GzbET3qhHIeLJMsqe9crLz0610HiZs3WMnIrAcZPQ0mWiu4x9aYw/Opyu7PHNNK4x60h3NnwVHnUmb0FbutxhZmJ6VR8DQ5uHc9ema19cT96TTWwX1OYkXMw4PWirZGZhgd6KDRWPKZ/NRmJz948EVNYyBWUgYIParN5AxmkJ+YZPGfeqiwtjd90Z7VImzpbWNLoYdA2RWXrOjLZMssQwjHGPerejStHMUB4HX0ra1aMTWLK/YbgaZOxyMMZGOBzV2FeORzSQx5GcVcijBIAHegGSwx5I4q/Enrio4k24x0qyiH0470CuSIvHNTImTSIuKnjHA/nTEKqYGKkUY69KXse9OAGeaBgFGOlSAHqe9Ki8etPUHI60EsRVzntUiAH8BQBz9PSpVGRigQKvI4rW0WTZdYz1rMQYyO1WrRjHMjDsaYM7qDlRmnuucGoLNt0amrZGRUkDIuGou13RmlQVJMuUpDPP7+IJeSgetV2XB68Vqa3HsvGOOtZ2OMetWUiIqe1NIqVhSMPXrSAjIyM1veGOr9uetYmOMdq2/DePNcUCex1SD5PwqMD5qnX7lRZ/eVIhLgfKa4HXOb1+OlegTj5D64rz/WsnUJAKpbDRmsPzpc47Up+lNyAcGkUOhAMyfUV6JaD/R1z6V5/aJuuYvqK9DtxtgH0oEyg6/vDUd18kRz1xVgLmX8aq6qcRscDgUyTz7WnMl69ZzoPrV27bdO7YzkmqrLzxx9aDUrsuOlRsPpVhj600Jl1HUk0g2Ox8FQbIN/qc1NrnLkAVc0CHyLJQOwqlqR3OfSmiepjiL96uOuRRV+2iy6nHGaKLFp2ONl0jALn5nbPA7c1m3GmspBCfKew9a9Ga2XGQgAB5zWdqEbKV8tAdvHSixKZylnaGEKCOW71Nrku23VEOWbg8dq0pjcBkBgypPUDgVh6kxlugijDZ5HpSGUYF5GBWhFEw5I960NJtY1zlMn1Na4hjcbCKAuYMKHINXlHYnmnT24hlK9uopwTj3pgkOUYOBUyjHQ81GB2qdFBXPegBVx07mngeuaFB4pw9DQSOVcD2qTHcimjtUi/doEAAP4VIoJAzSDGKkX3oAch7GplBWo8D/CpF9+RTA67SJPMt4yeuK1l5Wuc8PSZj2jsa6OP7tSyRMYNSHleajPWpv4fekByfiSPEyt68VhMvuetdX4lizbBwOQa5cjnmqQ0R/UUm3nkU85x1xSD0PWgYhGcYFbHhwYnasfBBrZ8PcXJFDB7HWKPlqE43mrC/cquR89SSOnH7r8K4DWFxfSknnNegyf6v8ACuA1oYv5cdM01sNGYwyaZxk4p7fQ03kdOf6Uyi3pq5vIgfWu/jGIPoK4TQ1LX0fsc13o/wBTzSE9ypEp3E9qy/ED+XaSHPatpOhNc34pfFvt7MaaEkcY3JJNVZRzVyQfUVXkjPWg06FYjpxzVrSYGmvV7gc1Awbmug8N2v8AGeppCOnhAitMDjisa5JZznpWtdnbEq1nIokfBHemSKqrFb7mGCaKg164FtakCii9jSKuXWMSRFn6k9Krq4kOI4x9etUWuzPcHI+Vegrb0mEBd5wD70zNlaS1mkQrtCLjnA5NYF3oUTz+YYzuPOe9d0MBOoI9aJbRJe4DEcGgXNY4VtPMUZ2NkDrTrOEKMk5+tbOp2xgSQgcnqOuawWufIkU7Ovb3pFJ3Ir5cyjIxgVEoHryKc8xmkZnxz6dqeqjjjFBQKvHbpT0Xocc0oHb04qRBjHfNArigYxil2809B6ipAPQfnQSMVcCpADnAH4UBTmnAYxQAY4HTIqRAD1xSKB07VKF44pgC9KeD6UAccdaVc7hyKANfQHCzMvTIzXWQH5a4rS223a/lXZ2pyo5qZE9R5p6cjmmvwaVW6UgKerxebZSDqcVxbgjgV6BKu5DnvXE6lD5N1IgHGeKqIFEqQKYBzUx5681H1zimUhCBWroPFyffvWYvXitTQR/pOaTEzrx/q/wqAj5qsD/VVD3qQHyD90a4LWx/xMJBXfsP3dcL4gG2+c+opoFuY7qaj7YB5qVhTAvNMo1fDke683dgK7Uj91yK5bwvF8zt+FdTKcKBSEyMDEZOK5Dxa2XRQevNdi4Pl1w3iZybwKOwpoEc7Kfm4zmoiTnBqVx83NRsMHIoNBqoZJAB1JrstIgEUK4Hauc0m2Ms4Y5wK61R5UQxQTIhuWDZA60QRbRupEwzZPNSXDbICemaYkcf4tussEB5LAGisPxBc+dfnByFaipd+hotDrrNPnJweDW3ESAixkkGucgkKSkYJOeTWnDdOF+Q84zyOlUjNm8D8pyCe1PSXDAZ+UcVkx3TMSSdvofepY2aQ5VuQfzoJsXbxBOpQjGOd1cdq9o0Up4xg4Ndq4wp3D5COo7Vl6tCJbYsQDxjNAJ2OOC4IqeMZ4zSOmJWX06U5OD/AEpFkgwOtSAdDTVHNSAYAoEPUZPtUi49OlNX1PT2qQe35UCAcjmn4OPakGe/OKkUZ60wFRdvWngdaQDHcU4emec0CBQMUoHPA59aF+nNPC9u9AEtqxSZG7g12li2UBriU685rsNMfdCh9qliL8gqM8VM/wB2oTzSAlQ7k965zxHBh1k9eK6CE84qnrdv51q/qORTWjGcawx+NJjH405hg4NJVAM79K1tBGbg1l9TW1oCHzcj1pMGdTj93VfHORVpuEqtjcxxUgSn/V8DrXF+I4yLnIHUV23HliuZ8Rw5w/YU4gcqRio8c8CrEide1Njj3uqjnnAplHT+GodtpuI5JzWtKctio9Oh8m0RfRaVmy9Ikll/1Occ15/rjBr6QnscV385xBz6V5zqTbrqU+retNbDRQkHORURXLcCpWBH9at6faszguDikWaekWxSNeOtaVy20Be9JCoSNaincs4pkdR8K5Huap69P9ntXOeAOK0LZe57cVzfi6YCBk9aY0cHcSeZc726ls0UxgBKv1oqDVHcDMcgZM4zzmrcUm0k4+QnH41mWVwku4dRnH61qRRDGXHXiqMmPSQs67sbSetaEQdNgU4HrnmqMMeAVx+fY1o2qkj9793HB96YmbUaeZAoc5xwc1B5CszRtjaelMjk+7k9KtxEHHpQScXrlqba6JGdrd8VRQbvwrtfEVh9ptC6D5gM4rikBQ4bIPSkWndEyj86kAwAajHUc1KM9qAHp35qYYBHrUMeN3ep1H+TQIVRzUg6e9Mxj6+lOHXFMB2O+KVecflQoJBFKPegQ5f5U4HjrzSKOQaeoANADlPNdRoZzbL+VcwBk10ugn9xj3pPYRst92oH46VO/wB36VXJqQYsbYYVNIgZCOtVQfmq1GcjaetAI4vUoDDcyJj5c5qqRg+1dH4itflWVR7GufIwB0qxkajn/Cuh8Px/dPcmsONdzha67RIPLi3GkwL0/CVVUktxU1y2TgVXBO6pAtocpisrVog8ZGM1pwnj0qtfAYP60LRgzh5Y8SEEd61NIsPnEzgewpLq1zeKV+6TzWzAmEAxjA6VTBsmZgqAdqgDnzBipZflA+lVkP77ODSEWrrJt/wrzu+XFxID6mvRpxutyR6VwOppi8kXuTmmtikVba23fMw6VtWkShQcUkcAESKB1GauRptUHtQDZDcOFwCeahiJdxxTrgbm+lLb4DcdaALQJSMk8d64HxXch5dn8q7y+mWK1YnsK8t1aXzrt298UMqJnNkuv1FFI7fvFGOc0VJqnYq6BrTRTiOVsDJAJ6HmvUtGkS7t85De3pXgttJiZuejGuv8OeIbjTZkKYdehVu4ppkzh2PXmtcnO33+tSlCAFPI6g0zw/q9rrFqrRMFcdVPUGtF7TbkDGBzkHpVXMWV4OOuTmrEbEHikEe0DPXFSAY9qBGlEVlj2sBux0rkfEWl/Z5jNGvyMefauktpirY71cljjvISjAHI5FSCdjzYc9hxUi+laOr6U9jMWAJhPRqztuaZZKnXkVKveoU9/WrCjsD09KBCgcdKcoHUdKAMelKCScdqYDh04oA7nrQR0pyj+VAhVP8AhUmM84pi479RTx1NADl6810fh7/VH0zXOr2610ugpstQxzzSewjVY/yqv6jvUzNwT+GKhA5J9KkBytt7Z9akRgT1queGz0BqROo44oAmuIlliZHGQa5C+tjbXLJzjtmuxXknnIrL1i282Itj5lppjMXTYhJcAEV18ShIVA6Vy+k/Lc4PfiuqA4H0okBWnXLDFRKMHGasS8n8KhBy3PWkImQFeSOOtQ3fINTAkg+1RXAyrHNAyjbQh5T9Kn2bWIPbpTtPj/eMR0qWddrZ5zQIqXGfT2qnKdgwo5q1IpOeSagkU4x70wJoJMxlH9K53V7FjeIUBOTzitdGJbC8nOKvw24UkuQW+lGw1oZaWoCZb0xUU6YXjkVpXOAxU/dFZF3cZbaPuimgKsigEnrUUZJcnpSzSZ4NJE2QB370xlbXpjHZOSTjHWvN5zl8k5JOa7nxbLixwO/auGlwB6Gky4lV/wDWr1GSKKWQZdfrRUFWucAshWZyD/Ef51sWcucZNc6smZX/AN41pWkuOhxSTOipE7fw/qk2m3SzQPxnlc8EV7NoOrQ6tZq8Zw2OVPWvnu0nIwM11nhrWJdOuEdCQM/MueCKtM5ZRue2MnygHp71C4I3DofejSb+LULVJoznctWZow/bDfzpmRURsEirEc23BU81XIOaFOMDmgLGkfKvYmjlAyeMetclqumPZy8AmEng+lbsUhDZ6EVoq0d1AUkA9896NgTODVQGqVRjHFauqaU1uxeEEx+npWYAc8UDTFzS5xxRgUdeKYx2c805dppmPwpwoEPHUU8dKjB7DnNOTkc9qAJoQ0kiovUnGK621QRQqnpWXo9nhBKwyzdPatYcdetJsQ4N6UhY7uDSKRu24pWwccjNSBG7ZIGM+lPUnHPeoc9R27VITgLg5piLMbflRcput3I6jmmJnAPrU8XKEHmkUc0g2XgC/wB6uoDcAZrKa1VL8noDyK1QOhJoYIjkpgXvjmp3xwabjPakBExwvPcVGy7+McU5+ZQKlVcAcd6AJLaMImAKiugGU47VaBCqe1U7lh0BoRT2KhUEZPNUrpiM4Ge3Wrh+UneeKa8Id8gcdaogisIDhnfp2q9jAz604YUADpimyHpzSGZWoygEqc57kVhTEYznkGte/UmRu+RkVlSqQg3fNk4q0CKZBIJbj6mpoV28nvzUezLH0zirKjkDHBoGc14qYMqKe5ziuRmAwcDpXReKJxLelRnagwOa5ubODzxUspbFN2zKuB3FFNYgOufUUUjWJ5iH/ev/ALxq/byc1jF8TP0xuNXLeTpzWMWdk43OjtZM4rYtJiMc8Vy9tLgiti0lGAQRitUctRHpPg/XzYTLHI2YWPOT92vV7K4S5hV1YFSMgg188Wk+CMmu+8Ga99ndbe4fCH7pJ6Ve5zzielXEWOSMZqoRtzxg1ftp1uIwQQRioriMgnP4UGZVBG4DvUkUpjcnJFQuCo61HuI6Z4pgbCSeauDg+xrPvNOglyy/u39aLeUoQTzVotvxjr1+tIDCn06WMfKN6+xqoUYNhgR9RXS7cH5SQe49aayqzZIH40Duc4Qc8CnKuee3vXQy2UM8fChX9ax7q3aCQq+Qe3vTC9ysq56f/rqURsBntSwoWkCqOasTQmPHegDV0++IjVCBwPzrSRw49M1zMWQwrbtJPmxyMevek0IvMnB24BpGXGPX1p+crkDg1MELKMZ4qR2Ku0nqKRQWINWXCrn1pIzzwKAGruxz2qaPrxzTwoPBpyw4PBpDsRyxh+QOamjw6gdxxinDC/Wo3yp3JQMdtyaQJ8p6808OCMkHPtSNLtHC0D0IRH84xT3wgGT3qJppicJGKrTK55kbBHagkW5ugp2j1pit5gPWmmFJc7c5qSCEqcdqYbkZUDP9aljT5O9SPENxJYfSs+71EWrlViZvrwKNwLbZGeDUbHrnp0qiNbj4DptP51YS6FyMwkH6CnYCC5i3NnJ6Vl3KEkKF+Ud/Wtx48qcnnvVO4XAx600Ix2hCtjg9uKbcARQu5OFUZ5qy6Ih68VkeI5vLtCmeCOaZSOKvX8+aRz65rNuAccE1oy8gms+5IJJHNSaGa4JYdxnpRSuMSqMd6KyqUlUd2XFnkTnEz/7xqeJ8YqvN/rn/AN4/zojbB61kj0mrmzby4rTtLjHHrXPwyY74q9BKQRg81omc84nVWs/vW3aXB6HFcjaT9Oa2rSfGMGtUckk0eq+ENfeJlgnclOgJr0aF0uYflIPevAbK5IIw2Md69F8Ga6SBbzPluxPeq3MZI6y4i2mq5QAZY8VpyEOgYYwaoSAZOMZ60EESuR0BqxEwPy5GOxFVWyGGD9aegxyOxpgXFI/D3oOW4I59KbG2457etToo+8eBSAkjGxR6+lR3kAuoTuGGHQjtTvvdAalRSF5zSAxLeIwTfPyOxq+0YdcKDvqeaBXByvX0p1rG0W7cD9adwKD27oMk8D0qxYsxbZjgc81amwyEgZ9qjto9uWUYb3ouBcjfYNpOOelTiUL3x7etZrOSc7TmrVpb5be5PIpMaJI1aVi3r0qwsTj+KpY1GOAMUpIz0qSrDV3g8jNOVsU9SOh6elMkXaCRQMa3Ld6UkMFwaYN2ck06JQgIPrwKBEyIOppHIAOAKYXOOtA+br0oHcYSTjrVacDPUnHarfTAPNVplzkjt+tAmQtyQF4arMQbZikgjBGe5qzHFlqGCRW8jJBZqklhhkUBkVsd8VPKuM1WDdB1oG9CpJp9sckRoD9BVdoPJPycY9Bir8j4yB29arStnrTRJGGyORzVa7UEH26VIT3qneSsFFNCMu4mCMdzYA5ya5fWr37RIQg+X1PetLWmbkds1hzpuXjjFMuJmyDAO3rWbdZGeK1JRgnis+6PB4pFdTHkz5g9CRRTpipdeMciikaI8hm/1r/7xpg60+f/AFr/AO8aZXMemSRvirkMo4zWeKlR8cU0yWrm5BPyMVr2dyQa5iKTkVpWs3I55rRSOapA7G0m3YwQP610Gm3JjdGU8iuJsrkqoyRW7ZXXzDLDBrRM5XGx7T4b1b7TCInYFgO9a8yjdx1647ivKtA1IwTJhsDPWvSILtZ4EdTl8VZi0TqOeevahQx98VEJN2R1P61Zs13H5sYHegRNBEW6gACpnJDdOM9qfgkkAfjQ8bbuPWkIIfmk45FW3U7V6Y7mi3twoBwc0X88NsgEkgDeg61IJCxLuOGqdowy4FZ+n3X2iZlRcJjr3rWgj+XBzihjSKflbe2B3460iRbWJHTvWkQuMFQR701kB+6KLjsZWFExHtmrkZzgVXmjKzFgO2M1JGSMfzoEXM/LgdaQEmmKc5BqZVz1pDGD25NTHlQSKjAOcdBUnO32oKQ0ECmv970prNyAO1Kc4oEN6DGakTIwKjXgjHenq2D06UAgOCM1AyhGJAxViQ8YA61WmPSgGT24+UHtVlSM1XtmBXA6ip1wCKRURlwO1VOnar8qBlqoyHGMcdqYSRTcErggc81BO5VPSrE7YbrwKpSktnvTMyGSRsDPXP4VTuXLDn/9VWZWwMnIqheTqsZBPGKpAYGtkbxjGKxmIK/Sr97J50nfb2qjIpAPY0GiKE6+nesq8XjBGfx6VsSZCHPWse9OAaRRjTDEox03UUTnLjtyKKTKR5NP/rX/AN4/zqMDjtUk3+tf/eNMrmPTCge1FHAoAkjfGMnpV2CTpWd0qSKTaaaZLSZ0FtMccECtqyuQAATXJwT+9aVrcdOc1pFnNUhc7uxuugB4r0TwpqHnRCJm+ce/UV45YXmGHNdNpeoNHIrRuVZehB6Vqmcsos9kRCxyc5PQitKAYUDgr3964jRfE0jKq3DA/XpXbWd3bTRgiRVJHciqZk1Y0ICEBzzTnuBj5Rn2qlcX9rCMPPHnH94VQl1eCRf3T5xSsI1JtQMansB0B7msKeZppsk5djyailuWuZQAcj0FbWnWccOJpRlz0U9qNgNPQ7QwRb5B87Dp6CtUttX0qlFJgZJ4NSPJvX6VI0yQvk8GnKSDVdWbIyePWnBzk5pAJP8AKc9qRFHanMc4yOKSIfMR27UAKgOcDj+tWEY55qrMQvzDtUf2tIwTnmmF7F0k54qRmAjNYsmpHOB09qgkvZXUKDtHt3osPmNiNxyeM0/eAetZtg5ZDySQatbiWxSFclk3Agjp7UqkDIbnNC/dxmgEHqB6UAK+dgweagcA/e61KewxTHGRntQBJbnAJHXNTeZjrUERwSKecZoHcsmQY56VUnnUqdmQac3HeoWOT05oG22V5BvGdvIqGVeOnJq7t+tMMQOSaZJhXQIXjIx6Vz18XfIAbb1rtZlyCEHPtWbfqCGXnHQ+lUgTscU421UdSTx+Nbt/Z+WSce+Kx2UhT2P0oKMufgMKxb7gmty74zkVh33Od3SkyjFuP9aMjuKKju2xKvPOR3opXLR5bN/rX/3j/OmU6bAmf/eP86b3rmPTDrS0UnegAzRmik79KAJY3IPNXrebkc81m+lORtpoTsS43OktbjFbdleBQOeK42CcjFatrc44raMrnNUpnoFhe5C8ityC7Py/MQfrXnthd7T14robK9BUYPFWmczi0zsYbgt/Fz71ftGaRwq/jXM2t0Dg9fWtazuzHIrKeaog7rS41hAJBLdq1opM8nOawNC1OOZhHKu1h75zXSLtZMjB4xmhmbJIpTk8+1TLNtPJ9iaqiUDdtOfqKj3sTwNvPNIRqJIGA64qRTzxWfFIRgYqxbliwGe/GaQXLm0gCpFG1Cx4wKZE24/zqDUbkRLtXkngD1oKKN7dMzFFGKrxQyzZJ+76mrVpZb8yTHJPOKu4wAMYp3EUVtEI+bOfc1BdQeTyvQ8VqBTngVDqEeYCT1ouBFpZyzL261oDG8cc5rN0n/WOPatMI+7OBSYIeMEZprckY7VJtwcHmkIHHpSGMJznFIOp4xTyuM+1IoyB60AInU4pzHGCR3pVBzSOOKBin5v60AelIpPHpUigHPb3oAjkwoycn2FNAaUAcAelP2+bJn+EdKtrGEX5QM0DSuUjAqc4+as68tiQdg//AFVtuKpzIRk8YoTBo5W6tzjDYB9u9c7qcAimIAO0813N9CDGWxk9q47XnBlU9wvNWSjmbsAFsfrWHen92Titq9PU1g6gxKnA6UmaHOXuTKucAZHaikujl0HfIoqWaxPNJh+9fH94/wA6Z2p83+uf/eNNrnPRA89KTtSg0daAE60UvT6UlAC96KOtFACqSDVyCcg9apUoJHShMTVzoLScjoa2bK7KgEGuPgnK4JrWs7jBFaxkc1SmdxaXYbGDya27S64XJ59q4SzueeDW5Z3hyDmtEzllGx3FldGORZEYhlOa73SdQWWJWDdRzn1ryezusgc1uWWpyW6ny2qkyGj0czqzcN3qVHHIycE9q4WHW5iw8zBHtWtba5E2AxOR6jimRY6lWYKMc1btidylvwyKxLW+SZB83fOQatpqFurACYtjrg8UmiTdlmEFuWJHSqNpG07GeXv93PYVnJdtqN2FAxCvb2rcQkKFHTtS2GWI02/SgoM96jDH39OKQuc0gLCDsetSPEkkRUjJPrVdDnHHParKHj3pFIoWsbRzYOB24q/t55OTUM3yvuqZWBAI70AhfbFIV4IpTjvTl5pFJERHIoC8nFOYHJpYxzTFYbt+akbrUzcA5qFWBbNIGJj2xQWIXaOp6mmyucYX8TUkABVTTEixEgRRT+gpoalYikajHPFVJcVabmq8oBpkSMzU2CwMfTrXAao2ZpMnua7zVT+6IOR6157rDlbiQehq1sStWYV6cg8g4rAvmwG6nNa16/XPFYd7J1xSZp1MO75kUA55FFJcA7wQRjdRUs0SPOZf9dJ/vH+dMFOm/wBbJ/vH+dNNc56IlLRjmk496AA+9B4o64NLQID2ooA/OjFIBKUe9B60UALU9vMVIqvSjjFMGr7m7a3PFa9pdbcc/jXJwSlcc1q21x6GtIyOedM7KyuuRzx9a3Le53Y6YriLSfAGDW5Y3XTBzWiZyyjY6yGTOB+tWoXZjjODWRaz5Iq6khBHOB3qjM3LWQg45/OtKBiR156msGCYMBg4NaVvcDAJPtTBo7bQ0xCCBw3U1uxKVwzdqwNGn3QIwwRjAxW3HLu2gsBnsaTMyyzKTx1pobkikMZwB1A6etPRMEk/hSAlUEj2qReBzUMjBcAduppBJluvXpSGWMBhimAlG5zikVueTTyQ4HrQMfuB7g05Tg9agEY7ClVD0oGmSSkA8nrSxOMHpmoJoN+3rwanhg24oBXuEgZuB0pohPB6VbVABzSOwApFcvcrNHwabEChwTxSvJubB4NNBz0/SmT6FnqODTc+9QiTbw3HvQ7ZGR160h3JGf0NQTPkZ/SoWnUg4YVBLKFAyQB707EtlTVmAhySeTivOdXbzLqUjux5rsNf1BVjKxkbu1cTdnknqavZBHuYl5k54NYt2MVvXLZyAKxLxNxIH50maGJc4Mgz6gYoqSeJjIMnuKKllpnmMv8ArZP940z8qfN/rX9dx/nTK5j0gPTFBFBooAOelFHelpgJ6GigUfWkIO1KaTpRQMAKU8GjFA60xBz1q3bTYPPWqn1pQSKYmrm/bzEcgiti0nOAc8Vy9rN0FatpL2z1rSLOacDtLC4BUdM1rW8gxya42ynKsOcZrobO4yOwrRHM1qdDBJt9OauQzc5JrGjlyoFXEf5cenemTsdHY6hJAMRORnr71s2msSBlJCsenSuNglxwTjPStCzn+bk07iaPSNO12ORQsiHP51rC4EqfIMD2rj9JXbEGIAZhnmtaPfvVlYgkdfSk0ZmoykjGeOtHJIHBHSo7e53DEv51ZMYbp+nSkAqNnrTs+n0puzBqQKT7UDJI255qZeOtRImBzirCEe2aktDlYAdKQygDNK3Q1FjJ9qCmPMvamM3P8qAM+x6VGVbP0oJbGvh/YikyQPbPapAuPmI5oIHemKxBI+fTNQlyDwce1TPHk5X9ao3TCIMz8Ad6aJZkX100M8ikDFZlzfyOmFOO3NSXkvmys7d+gqi656VY7FeSMzkljyfWsu5hKMw7Vqklc+9VLk5XHpSKRn2+lvc/NyFzjPc1Dc6BG2cSMD7iun0QLcW7IMhkPNOmtzn7pyT16UBc8t1WwNrdKG5BPX1orrPEun+ZEJFGSpz/AI0UrGkWfN03+tfj+I03jFOn/wBdJ/vGm1ynpiUUozig5NACDrS0nalNAAe1GBmj1pD70CFFFFB/WgYfWgUd6O9ACjAFHekFB680ASRvtatK3kziso59KsW8hU9cU0yJRudHaTepNbNlc4KjPFcvbS4wQK1YJuVINapnJONzr7ScFhtrZt5A688GuSsrjgZ4rbs7g8c5zVowasbfAHPWtPSAJbiJTwM81jLJuxk1raMxW+gwcZcc1QmdrbHDbQc45rWtSQBzkHtWbDHtc8jHf861LdScH+VDMmW/LB6c1LGWi+7kj0NQxkoD1xVyEBlHfPepBD0mQ/eBFSqVPKsKj8rPIxR5ZHakUT5HqKTcBnmolQ5HGalVT1oAEkJIBI/xqbj8Ki8sMOnTkU7ftGGXmgpabkhA602miVScc0wzKDyDSHdD80wn0qNps5wpqN2ZuM4FMm46WQL1PPpWXfMZ43XoccCrcuVGcVTlyWJGKaJZzkoxkY6GmJbSznCIT9K3YNNE85lk+56etaSW6IAF4x6Cm2O5ziaI7L+8kCg+gzSNocBP8Tnp1rpvLXbgjNIERSeMHrmi4GVo+iRW9zuRe3OTVrVbCNYmdVGR1rQWRYlLZrPu73zSV4x/OhXuBy19brJDtKkAnpRVq9+Vwe2eBRVMtHx7MMzPz/EaZxT5v9c/1P8AOmfSuM9YDRRRQAfrR+lFFABiijP/AOqjp060AL3oOB0pB9KUUAFJRRQAYpe9FFAAOKcCRzTRzS9qAL1u+e9adrJg89PSsOFsHGa0YH6EVcXYxnFHQ20uMDNdDYyYC5NcravlQTg1u2bfKDn8K1RyzVjpYJMEEVs2M3lyo45CkGuZtWJArbtHPGT1qkZWPTo5g4Ro/uOMg9KuxybU5HPcVzfh25+02jWzH94gJX3Fayuy5BzkA85qjNo14nzkhuTyB6VZhk+YAtg49KxImLANk8cE9KuQSsH+XkA/pSaFaxuJKPXr2qaOXNZSyMHBUggjirEcpP1HapsNM0lYE57etSKRjjFUImJB6/SrCHAyTSLUiyBSMisOeah8znvQJDnGcUh3QGD0IFIbbI5anFyM4oDnFArIb5Cd2oMcY7ZpWOc1Hnr9aAdkJcwh4TtG01izKUJBzurejO5evWszU02ur9geapMmXckj+VAoHQU5gBzTGYcYpWcY4b8qBCOcfzFRPgZ6mnMcjmoG5HPSgCKdlJPB6dc9KoTnZuI5OelWJEJPzYH9apyAtg+n+cVSAr34JSNiRk+tFOuwTAm0ZAPpRTKR8bzf66T/AHjTKfP/AK2T/eNR+lcZ64vOaD3xRRQAUg9aX6UZ60AHtR36UdaBQIDR7UUZpDFzSd6B+tHNMAHHFHc5ooPpQAvajpSc0vrigBQcGr9q+cDrWfU9u5BHNNEyWhv2kmDit6xbj6dK5i1flcVvWMnTnpW0TkqI6O1ccY49s1s2rHAORXPW7cAitqxYkjmqMGdNpFy9vcRSxnDKwNd2wDhZYj8ki7h9PT8K86tD83vXc6bIJLIRMxBj+YH+dUiJFyP5sg8DOD7VahjOwYP19qgiUhgSc+2OtXlbJzjAHeggfbg8I3TufWrMfy8/hVcc4OMY6Y61ZQHHse1IEWkanBuuelRp6VIBxzUjJF96Mc9KVemOtOGO1BVhDzzSDODUuFNIQv4UDsRHnpTScfSpmAFRleetAmhI25Aqlr7FLMnuTV1R8wrG8ST4KpninHcOhXtLzfiNz83QVfQnvzXM5wc9MVt6TdidQrkeYv61TRJfOCMEUyRQevHPWpdhHApkgyp7GpApSpz0O6qc4B6ZHPWtGQfMCD+feq0qnngj3qgKRT5NvAz0op5B3Z9xgdqKZSPjuazj81+X+8e/vTPsceQNz/nRRXGz1w+xxgHlv0o+yRgdWoooYALOP+8/5ihbSMg8t+lFFAw+yRnu350fZE4+Z/zoopCD7JH6t+lAtI8dW/OiigSD7JHjq36Uv2OPHVvzoooBiC0j9W/Sl+xx+rfmKKKYwNpH6t+lH2SPBOW/SiikAfZI/Vv0pyWiBuC3X2oopofQ07W2Tb95unrWzY2yYAy2PwoorWO5y1OpuW1uo7t0rasIFJQZbn3ooqzlkdDYRKJU5NdZpqf6QBk4xRRVozZuRxjaBz3qzHGNh69DRRQSTrGCDknjFWYlHl5yaKKkCaNBx15qTaOKKKQyRVFPVB+lFFIsUKKQqKKKADaCMUzaKKKAHIoJrl9cTN5gk4ooq47i6GUsY55NS2mY7hGUkHNFFUHQ65VBQU1kBU5+tFFQIryxqTj0qsYlJbrxRRTQiu0YOOvUfzoooplI/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior radiograph shows a displaced fracture of the base of the 2nd metacarpal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Josh Bloom, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_19_4415=[""].join("\n");
var outline_f4_19_4415=null;
